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Alzheimer's disease is a progressive neurodegenerative disease affecting large 
numbers of population, especially elderly. The disease is characterized by loss of 
neurons and two pathological hallmarks, amyloid deposits and neurofibrillary 
tangles (NFT). NFT are composed of abnormally hyperphosphorylated 
microtubule-associated proteins (MAP) tau. Normally, tau promotes the 
polymerization of microtubules and stabilizes neurites formation, which is 
phosphorylated at low level in normal adult brain. However, the imbalance of 
protein kinases and protein phosphatases activities contribute to the excessive tau 
phosphorylation and NFT formation. This may hinder microtubule assembly, 
disrupt axoplasmic and dendroplasmic transports, and cause neuronal death. 
Therefore, reducing the level of tau phosphorylation is one of the rational 
strategies for prevention or treatment of the disease. 
Flavonoids are polyphenolic compounds, produced widely in fruit, vegetables and 
nuts. Flavonoids are normally consumed in diet which is estimated from 6 to 64 
mg/day.，They have been shown to have a wide range of beneficial effects to 
health, including maintenance of capillary wall integrity, anti-inflammatory effect 
and antitumor. Moreover, flavonoids have also been reported to protect neuronal 
death by scavenging free radical in the primary neuron from rat but many studies 
have shown that it is unlikely to be the sole explanation for their neuroprotective 
function since some molecules (e.g. Vitamin C) with high antioxidant activity can 
not protect neuronal death. 
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In this study, an assay based on the protection of tau hyperphosphorylation 
induced by okadaic acid in neuroblastoma cell line was developed. The assay is 
aimed to search for neuroprotective efficacies of naturally occurring flavanoids. 
The differentiated human neuroblastoma SH-SY5Y was treated with okadaic acid, 
a protein phosphatase inhibitor, to induce the hyperphosphorylation of tau protein 
and cell death, which were confirmed by western blotting analysis. After 
characterization, the model was used to search for any flavonoids with the ability 
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Chapter 1 Introduction 
1.1 Alzheimer's disease 
Alzheimer's disease (AD) is the most common neurodegenerative disease that 
usually affects people over age 65. It is an irreversible and age-related disorder, 
which causes the patients with AD losing their memory and cognitive ability 
gradually, and having difficulties in movement and a dramatic change in 
personality. At the last stage of AD, patients will lose the capacity to take care of 
themselves and are dependent on other people. In many developed countries, AD 
is a major health-care problem that puts a heavy economic burden on society 
because the cost of hospitalization and nursing care is increasing due to the rise in 
the population over the age 65 and the increase of the AD patients (National 
Institute on Aging, 2000). 
With the intensive study of AD for over three decades, the mechanism of the 
pathogenesis of the disease is beginning to be understood. Two distinct hallmarks 
of this disease were discovered: the deposition of P-amyloid (Ap) plaques and 
neurofibrillary tangle (NFT) in brain (Alzheimer, 1907). According to these two 
hallmarks, two hypotheses were proposed. The first hypothesis is known as beta-
amyloid hypothesis. In this hypothesis, it states that Ap plaque is formed due to 
the aggregation of large amount of Ap protein and other molecules, e.g. 
apolipoprotein, ubiquitin. The major component, Ap protein, is resulting from the 
cleavage of a plasma membrane protein known as amyloid precursor protein 
(APP) (Selkoe, 1994). The other hypothesis is taupathy hypothesis which explains 
that the neurofibrillary tangle is formed by the aggregation of paired helical 
filament (PHF) that is composed of hyperphosphorylated tau protein (Lee et al” 
1991). Both of these depositions may cause neuronal death and neurodegeneration. 
1 
Apart from the two hypotheses, many mechanisms have also been proposed to 
explain the pathology of AD. One of the hypotheses, cholinergic hypothesis, 
suggested that the loss in cholinergic function was thought to be responsible for 
the symptom of AD. However, there is still no definite treatment that can stop or 
reverse the neurodegenerative process. 
1.1.1 Cholinergic hypothesis 
The cholinergic hypothesis was initially presented over 20 years ago and suggests 
that a dysfunction of acetylcholine containing neurons in the brain contributes to 
the cognitive decline observed in those with advanced age and Alzheimer's 
disease (Terry and Buccafusco, 2003). This premise has since served as the basis 
for the majority of treatment strategies and drug development approaches for AD 
to date (Giacobini, 1991). 
1.1.2 p-amyloid hypothesis 
The p-amyloid hypothesis suggests that accumulation of Ap plaques in the brain 
and the associated signaling response may contribute to the cause of AD. This 
hypothesis is established mainly by the study of mutations in familial patients. 
The mutation genes including APP, presenilin 1 (PSl) and presenilin 2 (PS2) 
were found to be related to the onset of familial AD. Moreover, the cloning of the 
gene encoding the APP and its localization to chromosome 21 suggested that 
trisomy 21 (Downs syndrome) leads invariably to the pathology of AD (Lemere 
et al., 1996). There are at least three enzymes including a-secretase, p-secretase 
and y-secretase, involving in the cleavage of APP to produce secreted form of 
amyloid protein. However, the mutations promote the generation of A|3 by 
2 
favoring proteolytic processing of APP by P-secretase and y-secretase. 
Furthermore, APP mutations inside the A|3 sequence promote self-aggregation of 
AP. There are two major forms of Ap: Ap40 and Ap42, which have 40 and 42 
amino acid residues respectively. Although Ap42 is the minor product, it plays an 
important role in AD pathogenesis because Ap42 is easy to aggregate into plaques 
than Ap 40 (Jarrette et al., 1993). The Ap plaques formation can recruit reactive 
glial cells which produce pro-inflammatory cytokines for inducing inflammatory 
response. The response generates excessive reactive oxygen species, damaging 
proteins, lipids and the cells. Moreover, the plaque accumulation can alter ionic 
homeostasis, particularly calcium ions. The excessive calcium entry eventually 
causes cell death (Mattson et d . , 1992). 
1.1.3 Taupathy hypothesis 
Paired helical filaments (PHF) are the major building blocks of neurofibrillary 
tangles. They are composed of hyperphosphorylated tau protein. Tau protein 
isolated from normal adult brain contains 2-3 moles of phosphate per mole of tau 
protein while from the brain of AD adult; it contains 5-12 moles (Selden and 
Pollard, 1983). Tau is predominantly expressed in axons, which is a group of 
microtubule-associated protein that normally promotes and stabilizes the 
assembly of microtubules (Hong et aL, 1997). In adult human brain, there are six 
isoforms of tau ranging from 352 to 441 amino acids. All six isoforms are 
phosphoproteins (Wood et aL, 1986). About half of the known phosphorylation 
sites in tau are serine or threonine residues followed by a proline. Paired helical 
filament-tau differs from normal tau by its abnormal hyperphosphorylation, which 
reduces the binding affinity of tau to microtubule. It has been shown that 
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hyperphosphorylation tau does not bind to microtubules unless it is enzymatically 
dephosphorylated (Sontag et al, 1999). This reduced amount of normal tau may 
lead to the destabilization of microtubules and result in impairment of axonal 
transport, neuronal degeneration, and the aggregation of paired helical filaments. 
Therefore the hyperphosphorylation of tau is believed to be a key event in the 
pathogenesis of Alzheimer's disease (Lee et al” 1991). 
The phosphorylation of tau is regulated by kinases and phosphatases. Normal tau 
can be phosphorylated by many kinases, such as glycogen synthase kinase 
(GSK)-3a and -3p, cyclin-dependent kinases 5 and mitogen-activated protein 
kinase (MAPK). The phosporylation state of a protein can also be regulated by 
protein phosphatase. If the the expression level or the activity of protein 
phosphatase reduce, tau phosphorylation will increase due to the lack of 
dephosphorylation by phosphatase. The expression level of two phosphatases, 
phosphatase 2A and phosphatase 2B, were shown to be reduced in AD brain than 
normal brain (Gong et al., 1995). This links to the tauopathy hypothesis 
suggesting that hyperphosphorylation of tau is a key event for the pathology of 
AD. 
1.1.4 Current therapies 
There is currently no effective treatment for Alzheimer's disease (National 
Institute on Aging, 2006). Currently available medications only offer 
symptomatic benefit for some patients but do not slow the progression of the 
disease. Acetylcholine esterase inhibitors are the only group of medicine being 
approved by FDA for symptomatic treatment of AD (Enz and Gentsch, 2004). 
These drugs do not slow down the disease progression, but they can temporarily 
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stabilize cognitive impairment and maintain body muscle function, often delay the 
needs for patient placement in nursing homes by several months (Terry and 
Buccafiisco, 2003). Discovery of the mutation genes in early onset AD is critical 
in exploring the role of amyloid plaques in neuronal cell death, and designing 
mechanism-based drugs. These include inhibitors for A(3-generating proteases, 
agents for preventing AP oligomerization and immunotherapies to reduce Ap in 
brain. Discovery of neurofibrillary tangles formed by aggregation of 
hyperphosphorylated tau proteins in AD brain has led to strategies for identifying 
selective inhibitors of tau kinases, modulators of phosphatase and brain-permeable 
drugs that help maintain microtubule integrity (Michaelis, 2002). 
1.2 Proteins involved in Alzhemer's disease 
1.2.1 Acetylcholinesterase (AChE) 
Acetylcholinesterase is the main enzyme involved in cholinergic 
neurotransmission. It can break down the acetylcholine (ACh), which is a 
neurotransmitter synthesized in certain neurons by the enzyme choline 
acetyltransferase, and allow control of muscle contraction (Ellis, 2005). Cognitive 
deterioration in AD is related to progressive loss of cholinergic neurons and a 
decline in levels of acetylcholine in the brain, particularly in the temporal and 
parietal neocortex and hippocampus. Inhibiting the activity of 
acetylcholinesterase can increase the level of acetylcholine in synapses and 
enhance the cholinergic function which provides the symptomatic improvements 
in treated with cholinesterase inhibitors. Several acetylcholinesterase inhibitors 
have been approved by FDA for symptomatic treatment of AD, including 
Donepezil and galantamine (reversible AChE inhibitors), and rivastigmine (a 
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slowly reversible inhibitor) (Ellis, 2005). It has been reported that AChE is co-
localized with amyloid plaque and forms a stable complex with the plaque. 
Moreover, the neurotoxicity of the plaque is increased by the presence of AChE 
(reviewed by Talesa, 2001). 
1.2.2 p-amyloid 
The amyloid precursor portein is a transmembrane glycoprotein that is 
proteolytically processed by two competing pathways, the non-amyloidogenic and 
amyloidogenic (beta amyloid forming) pathways. Three major secretases are 
involved in the proteolytic cleavage of APP. These include a-secretase, beta APP 
cleaving enzyme (BACE, formally known as p-secretase) and the y-secretase. The 
a-secretase cleaves within the Ap domain of APP generating non-amyloidogenic 
fragments and a secreted form of APP (a-APPs). In the amyloidogenic pathway, 
BACE cleaves near the N-terminus of the Ap domain on the APP molecule, 
generating another soluble form of APP, p-APPs and a C-terminal fragment (C99) 
containing the whole Ap domain. The final step in the amyloidogenic pathway is 
the intramembranous cleavage of the C99 fragment by y-secretase, to form the A(3 
peptide (reviewed in Verdile, 2004). Excessive production of P-amyloid promotes 
the formation of neurotoxic amyloid plaque, which can induce neuronal cell death 
and recruit reactive glial cells producing pro-inflammatory cytokines. The 
inflammatory response generates excessive reactive oxygen species, damaging 
proteins, lipids and the cells (Mattson et a\., 1992). 
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1.2.3 Paired helical filaments (PHF) 
Microtubules are required for the formation of the neuronal cytoskeleton and 
axonal transport. Alzheimer's disease (AD) is characterized by existence of paired 
helical filaments (PHF) in certain selected brain neurons, especially in 
hippocampus. PHF exist as neurofibrillary tangles in neuronal cell bodies, as 
neuropil threads in the dystrophic neurites of affected neurons, and in 
degenerating neurites surrounding the extracellular amyloid in senile plaques. 
Microtubule-associated protein tau is the major protein subunit of PHF (Grundke-
Iqbal et al, 1986). Tau in AD brain is abnormally phosphorylated. The 
abnormally phosphorylated tau from AD brain contains 5-9 mol of phosphate/mol 
of the protein, which is about three to four times the level of phosphate in normal 
brain tau (Kopke et al, 1993). PHF-tau is phosphorylated at multiple sites (Iqbal 
et al., 1989). There are 21 abnormal phosphorylation sites of PHF-tau (all Ser/Thr 
sites) identified either by phosphorylation-dependent (Kanemaru et al, 1992) or 
by mass spectrometry (Hasegawa et al., 1992). Most of the phosphates are 
clustered at two sites, one amino-terminal (Ser-198 to Thr-217) and one carboxyl-
terminal (Ser-396 to Ser-422) to the microtubule-binding repeat domains (Gln-
244 to Gly-367). As a result of the abnormal hyperphosphorylation, the molecular 
weight of PHF-tau on SDS-polyacrylamide gels is higher than that of normal tau 
(Lee et al., 1991). Furthermore, PHF-tau does not promote the assembly of 
microtubule unless it is dephosphorylated before its interaction with microtubule 
(Iqbal et al,, 1994). 
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1.2.4 Protein kinases 
Protein phosphorylation is believed to be one of the major mechanisms for 
regulation of cellular function. Tau is a phosphoprotein which was discovered and 
best known for promoting the assembly of microtubules (Weingarten et al., 1965). 
The interaction of tau with other brain proteins appears to be regulated by 
phosphorylation. The in vitro phosphorylation of tau has been reported to inhibit 
both the polymerization of tubulin (Lindwall and Cole, 1984) and the interaction 
of microtubules with actin filaments (Seldon and Pollard, 1983). The abnormal 
phosphorylation of tau in neurons in AD might take place over a long period of 
time. The neuronal microtubule-associated protein tau is a target of 
phosphorylations on a large number of sites, and a substrate for several kinases 
according to the in vitro studies. Some of these are proline-directed kinases, e.g, 
MAP-kinase, GSK3b and Cdk5, while other enzymes including MARK kinase, 
protein kinase A and others are nonproline directed kinases (Grundke-Iqbal et al, 
1984). Studies have claimed that some of tau phosphorylating kinases, such as 
GSK-3 beta, MAP-kinase, microtubule-affinity regulating kinase MARK and 
Cdk5 phospohorylate tau at sites that are elevated in Alzheimer's paired helical 
filaments (PHF). Hyperphosphorylations could lead to structural alteration in tau, 
and decrease in its interaction with microtubules (Binder et al, 1985). It is 
possible that these kinases could be sensitive to changes in their regulatory 
patterns or at the structural level, thus participating in the molecular pathway 
leading to neurodegeneration. 
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1.2.4.1 Glycogen synthase kinase-3 (GSK-3) 
Glycogen synthase kinase 3 (GSK-3), a multifunctional serine/threonine kinase, 
was initially found to be able to phosphorylate and inactivate glycogen synthase 
which is the final enzyme in glycogen biosynthesis (Hughes et al, 1993). The 
inactive glycogen synthase then results in dramatic reduction of glycogen 
synthesis. GSK-3 is also a key regulator of numerous signaling pathways� 
including cellular response to Wnt, receptor tyrosine kinase and G-protein-
coupled receptors and is involved in many cellular processes, including cell cycle 
regulation, cell proliferation, microtubule dynamics and protein synthesis 
(Prickaerts et al, 2006). GSK-3 is unusual in that it is normally active in cells and 
is primarily regulated through inhibition of its activity. However, if the pathways 
in which GSK-3 acts as a key regulator is dysregulated, it will lead to 
development of human disease such as bipolar disorder, diabetes, cancer and AD 
(Doble and Woodgett, 2003). 
V 
1.2.4.2 Cyclin-dependent kinase-5 (CDK-5) 
Cdk5 is a Ser/Thr protein kinase with postmitotic activity that phosphorylates 
KSP protein motifs on MAP lb protein, KSPXK protein motifs on tau (Kobayashi 
et al, 1993) or KSPXX on neurofilament proteins, actinbinding protein 
caldesmon and proteins of the synaptic vesicles (Sun et al, 1996, Shetty et al, 
1993). This kinase was identified and characterized as a brain proline-directed 
kinase (Lew et al, 1992). Cdk5 was shown as an active enzyme in postmitotic 
cells such as neurons, and as a kinase that phosphorylates tau protein (Paudel et 
al” 1993). After these discoveries, protein responsible for activation of brain 
Cdk5 was found. The Cdk5/p35 system participates in normal development of 
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neuronal cells and the axonal growth (Paglini et aL, 1998). Therefore, Cdk5 is 
treated as one of the important kinases phosphorylating tau in neuronal cells. 
Cdk5 was identified on the basis of biochemical similarities to Cdc2 protein 
kinase, a regulator of mitosis. Unlike Cdc2, Cdk5 is not found in dividing cells, 
and exhibits a preferential distribution in brain differentiating neurons (Kobayashi, 
1993). The formation of a stable Cdk5/p35 complex following phosphorylation of 
Cdk5 in hippocampal neurons has been postulated as a factor responsible for 
constitutive activation of this protein kinase. As a consequent� i t increases in 
phosphorylation at sites that have been found in tau pathology (Alvarez, 1999). 
1.2.5 Protein phosphatase (PP) 
In contrast to the protein kinases that have been discovered, relatively few protein 
phosphatases are known (Andreassen et aL, 1998). In this regard protein 
phosphatases were often considered as the poorer cousins of kinases. However, it 
is acknowledged that the regulation of protein phosphorylation requires the 
control of both kinases and phosphatases and that the regulation of phosphatases 
is as complex as that of kinases. In many ways, the phosphorylation-
dephosphorylation cycle can be regarded as a molecular "on-off switch although 
this is probably an over simplification of the processes involved (Ling et aL, 
2004). The end result of these associated pathways is the regulation of many 
different cellular processes, i.e. glycogen metabolism, calcium transport, muscle 
contraction, gene expression, protein synthesis, intracellular transport, 
phototransduction, cell cycle progression and apoptosis (McCluskey and Sakoff, 
2001). 
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Several phosphatases like protein phosphatase 1 (PPl), PP2A, PP2B, and PP2C 
have been implicated in dephosphorylation of tau. However, only PPl, PP2A, and 
PP2B have been shown to dephosphorylate abnormally hyperphosphorylated tau 
(Gong et al, 1994). Although PP2C can dephosphorylate tau when it is 
phosphorylated by PKA in vitro, it is not capable of dephosphorylating the 
abnormally hyperphosphorylated tau isolated from AD brain tissue (Gong et al, 
1994). It seems that PP2A is the phosphatase that acts on most phosphorylation 
sites of tau (Goedert et al, 1995) PP2A is composed of three subunits, A, B, and 
C, and the B subunits are mainly involved in substrate recognition. PP2A binds to 
tau through its tubulin binding region (Goedert et al, 2000). Mutations in this 
region could decrease the capacity ofPP2A to bind to tau and produce an increase 
in tau phosphorylation. 
1.2.5.1 Protein phosphatase 1 (PP-1) 
Protein phosphatase 1 (PPl) is enzyme involved in a wide array of physiological 
processes, including glycogen metabolism, muscle contraction, and gene 
expression. The role of PPl in these diverse aspects of cellular physiology has 
been difficult to understand the philosophy behind by using available inhibitors 
because of a lack of pharmacological specificity (Allen et al., 2004). One 
approach to identifying specific targets for the enzyme is elaborating on the 
control mechanisms that direct PPl activity toward specific substrates. This 
strategy leads to characterization of multiple regulatory subunits, and many of 
these proteins are shown to either promote, or to inhibit, PPl activity toward 
substrates in specific settings (Cohen, 2002). 
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In the nervous system, PPl plays a role in the regulation of synaptic plasticity by 
controlling activity of a broad range of ion channels and signal transduction 
enzymes (Greengard et ai, 1999 and Lisman and Zhabotinsky, 2001). As in other 
tissues, the PPl activity toward its various targets in brain likely depends on 
association with different regulatory subunits. Some of the neuronal regulatory 
subunits have been well characterized. Within the basal ganglia and cortical 
regions, multiple neurotransmitters act through convergent biochemical pathways 
to control PPl activity by the regulatory molecule, dopamine- and cAMP-
regulated phosphoprotein-32 kDa (DARPP-32) (Greengard et al, 1999). A 
protein structurally related to DARPP-32, inhibitor-1, has been implicated in the 
PPl inhibition required for the induction of longterm potentiation at hippocampal 
synapses (Allen et al., 2000). 
1.2.5.2 Protein phosphatase 2A (PP-2A) 
PP2A is involved in a broad range of cellular processes, including membrane 
receptor desensitization, signal transduction, transcriptional regulation and control 
of DNA replication, and mitosis. This diversity of PP2A function is due to a 
diversity of targeting/regulatory subunits and several levels of post-translational 
modification (McCright et al, 1996). PP2A exists in the cell as a heterotrimeric 
complex consisting of a 36-kDa catalytic C subunit, a 65-kDa 
structural/regulatory A subunit, and a variable regulatory B subunit. The A and C 
subunits are each encoded by two highly related (85 and 97% identity, 
respectively) and widely expressed genes. The variable B subunits identified to 
date are encoded by three unrelated gene families (Veerle and Jozef, 2001). The 
most prevalent isoform, named variously PR55, B55, or simply B, is encoded by 
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at least three genes with several splice variants (DePaoli-Roach et cd., 1994). The 
PR72/130 regulatory subunit is encoded by a single gene that generates two splice 
forms that vary in the size of their amino terminus (Hendrix et al, 1993). 
1.2.5.3 Protein phosphatise 2B (PP-2B) 
PP2B (calcineurin, Ca^^ / calmodulin dependent protein phosphatase) is a 
heterodimer with A and B subunits that share some overlapping substrate 
specificity with both PPl and PP2A (Wera and Hemmings, 1995). PP2B A 
subunit, a 60kDa catalytic subunit, has a 40% homology with the catalytic 
subunits of PPl and PPA, but contains an additional 170 C-terminal amino acids 
which is the calmodulin binding domain. The B subunit has a molecular weight of 
19kDa with four Ca^"^-binding sites. PP2B is modulated by Ca^^, calmodulin, and 
possibly by FK506-binding proteins and the cyclophilins (Griffiths et al., 1995). 
PP2B shows relatively low activity in the heart, spleen, liver and testes but is 
expressed highly in brain tissue, particularly in the striatum and hippocampus and 
localised along dendritic spines. This is consistent with its proposed role in 
memory by modulating long term potentiation and long term depression of 
synaptic efficacy (Mitsuhashi et al, 2000). Over expression of PP2B in transgenic 
mice produced deficits in long-term memory and a constraint on long term 
potentiation. Other neurological studies have shown PP2B to be highly expressed 
in areas of the brain, which are vulnerable to stroke, epilepsy and 
neurodegenerative diseases. It has been suggested that high level activity of PP2B 
predisposes neuronal cells to apoptotic cell death and that PP2B inhibitors reduce 
such susceptibility (Asai et aL, 1999). Some of the neurological and physiological 
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and abnormalities of Downs syndrome may also be attributed to PP2B inhibition 
(Fuentes et al, 2000). 
1.2.6 Apoptotic and Anti-apoptotic proteins 
Neurodegenerative diseases are characterized by dysfunction and death of specific 
neuronal cells and the presence of intracellular and extracellular aggregates of 
soluble proteins, a common feature in several disorders of the central nervous 
system (CNS), such as AD, Parkinson disease (PD) and Huntington's diseases 
(HD) and Amyotrophic Lateral Sclerosis (ALS) (Selkoe, 2004). 
Neuronal death can occur through necrosis or apoptosis, both processes involving 
mitochondrial function (Ankarcrona et al., 1995). Necrosis is a rapid type of death 
resulting from an acute event that leads to complete failure of mitochondrial 
function and cellular homeostasis. Apoptosis is, instead, a slow and active process 
triggered by less severe stimulates and this might be due to the mechanisms for 
neurons to delay death, e.g. various neuroprotective programs activated involving 
molecules and genes with anti-apoptotic function (Mattson, 2000). For the 
apoptotic process, it is characterized by cell shrinkage, plasma membrane 
blebbing, nuclear chromatin condensation, DNA fragmentation and increase of a 
number of apoptotic markers, e.g. caspase and Bel protein families. Moreover, 
mitochondria play a pivotal role in cell decision, which is supposed to depend on 
a balance between apoptotic and anti-apoptotic signals (Lilia and Maria, 2006). 
In fact, the initial trigger induces some toxic events and/or synergizes with other 
apoptotic cascades, thus causing a persistent imbalance of neuronal homeostasis, 
mitochondrial dysfunction and neuronal death. 
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1.2.6.1 Caspase-3 
Caspases are a group of cysteine proteases that cleave proteins after aspartic acid 
residues (Alnemri et al., 1996). To date, there are 14 known caspases that are 
divided into two main classes: initiators (or activators) and executioners (or 
effectors). Caspases exist as immature pro-caspases that must first be cleaved in 
order to become active. It has long been understood that caspases are essential 
proteins for the induction of apoptosis (Cohen, 1997). 
Caspase-3 is considered as the primary executioner caspase because it cleaves 
other important proteins to induce apoptosis. Caspase-3 induces apoptosis by: 
cleaving Inhibitor of Caspase-Activated DNase (ICAD)，which then allows 
Caspase-Activated DNase (CAD) to cleave DNA into fragments; cleaves nuclear 
laminins, which allows the nucleus to condense; and it cleaves PAK-2, which 
plays a role in membrane blebbing; among other things. DNA fragmentation, 
nuclear condensation, and membrane blebbing are all hallmarks of apoptosis 
(Wolfe/ a/., 1999). 
Caspase-3 has been extensively studied with respects to its role in apoptosis. It 
has been shown that active caspase-3 is expressed in neurons, astrocytes, and 
oligodendrocytes (Mouser et al., 2006). It has been showed that active caspase-3 
is present in the brain during the early stages of development, but present in 
limited amounts in postmitotic neurons in later stages of development (Lesuisse 
and Lee, 2002). 
1.2.6.2 Bcl-2 
The Bcl-2 protein family has an important role in intracellular apoptotic signal 
transduction. This family includes both anti-apoptotic and pro-apoptotic proteins 
that contain one or more Bcl-2 homology (BH) domains (Merry and Korsmeyer, 
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1997). The major anti-apoptotic members of the Bcl-2 family, Bcl-2 and Bcl-x, 
are localized to the mitochondrial outer membrane and to the endoplasmic 
reticulum and perinuclear membrane. Some studies have shown that Bcl-2 can 
support the survival of neurons in the absence of NGF and the overexpression of 
Bcl-2 can override the death signal induced by the withdrawal of a trophic factor 
(Garcia et al.’ 1992). Moreover, transgenic mice expressing Bcl-2 in the nervous 
system has found to be protected against neuronal cell death during development 
(Martinou et al.’ 1994). 
The expression of Bcl-2 is high in the central nervous system during development 
and is down regulated after birth; however the expression of Bcl-2 in the 
peripheral nervous system is maintained in whole life. Although the development 
of the nervous system in Bcl-2-knockout mice is normal, there is a subsequent 
loss of motor, sensory and sympathetic neurons after birth, suggesting that Bcl-2 
is crucial for the maintenance of neuronal survival (Veis et al, 1993). 
1.3 Flavonoids 
The flavonoids are a group of polyphenolic compounds widely distributed in the 
plant kingdom. More than 6400 known flavonoid compounds have been 
discovered. Flavonoids contribute to the flavor and pigment of the fruits and 
vegetables and they also have important roles in plant growth, reproduction, and 
pathogen resistance (Harbome and Williams, 1992). They have a Ce-Cs-Ce 
flavone skeleton in which the three-carbon bridge between the phenyl groups is 
commonly cyclized with oxygen. Flavonoids can be divided in several classes 
based on the degree of unsaturation and oxidation of the three-carbon segment 
(Peluso, 2006). Usually, they are present in plants either as aglycones or as 
1 6 
glycoside conjugates including glucose, arabinose, glucorhamnose, galactose, and 
lignin (Ross and kasum, 2002). The contents of flavonoids in common foods may 
be obtained from United States Department of Agriculture databases. 
1.3.1 Biosynthesis of flavonoids 
Flavonoids are synthesized by the phenylpropanoid metabolic pathway in which 
phenylalanine is used to produce 4-coumaroyl-CoA. Then it will be combined 
with malonyl-CoA to produce the true backbone of flavonoids, i.e. chalcones, 
which contain two phenyl rings. Conjugate ring-closure of chalcones results in the 
three-ringed structure of a flavone. The metabolic pathway continues through a 
series of enzymatic modifications to yield flavanones 一 dihydroflavonols — 
anthocyanins (Fig.l). Moreover, this pathway can also produce many other 
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Fig. 1.1: Diagrammatic representation of the phenylpropanoid metabolic 
pathway. Source from: (Winkel-Shirley, 2001) 
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1.3.2 Biological functions of flavonoids in plants 
An important role of flavonoids is to serve as visual signals for animals in 
attracting pollinators in flowers, and later for animals eating the fruits and helping 
in seed dispersal. In fruits, flavonoids may also contribute as color, flavor or 
texture to fruit quality. They are also involved in the formation of undesirable 
brown colour in fruits after cutting and bruising (Amiot et a!., 1997). 
The composition of flavonoids varies greatly in different fruit species (Roberts 
and Antolovich, 1997). Anthocyanins are pigments that contribute red, violet and 
blue color to fruits. The main anthocyanins in fruits are glycosides of six 
anthocyanidins. The other predominant flavonoid group in fruits is 
proanthocyanidins and their monomer units, catechins or gallocatechins, which 
are the natural substrates of polyphenol oxidases and are involved in the browning 
phenomenon of fruits. 
In addition to acting as pigments in fruits and flowers, flavonoids are involved in 
many biological functions in plants. They play an important role in the plant-
microbe interaction and in sexual reproduction by promoting the pollen tube 
development (Koes et aL, 1994). Flavonoids also have apparent roles in plant 
stress defence, such as protection against damage caused by attack of pathogen 
and UV-light. Flavonoids, mainly anthocyanins are responsible for the colour 
changes of plants during autumn, which have been suggested to protect leaf cells 
from photo-oxidative damage (Feild et aL, 2001). 
Flavonoids are strongly UV-absorbing compounds, and accumulate mainly in the 
epidermal cells of plant tissues after production caused by UV-induction. The 
epidermal layers of plants can absorb 90-99% of the UV radiation and serve as 
shields against this harmful radiation (Robberecht and Caldwell, 1983). 
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1.3.3 Beneficial effects of flavonoids on human health 
Flavonoids are polyphenolic compounds which are rich in many foods in our diet. 
For example, tea, coffee, chocolate, wine, and beer have high amount of 
polyphenols contributing to the in vitro antioxidant capacity. Flavonoids have 
been investigated actively and they have possible beneficial influence on human 
health. Flavonoids have been found to have potent antioxidant and free radical 
scavenging activities in vitro (Halliwell, 2007). Moreover, there is growing 
evidence from human consumption studies supporting a protective role of 
flavonoids in cardiovascular diseases and cancer. Nevertheless, many flavonoids 
have been found to possess antiviral, antibacterial, antifungal or anti-allergenic 
properties. However, their possible interactions with other substances and their 
metabolism in the human system are still under detail investigation. 
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Chapter 2: Materials and Methods 
2.1 Differentiation of SHSY-5Y cells 
2.1.1 SHSY-5Y cell culture 
SH-SY5Y human neuroblastoma cell was maintained at 37°C in the presence of 
5% CO2 in Dulbecco's modified Eagle's medium- F-12 (DMEM/F-12) (Gibco), 
supplemented with 10% fetal bovine serum (FBS), 1 OOU/ml penicillin and 100|j.g 
/ml streptomycin (Invitrogen). For every 3-4 days, the old medium was dispensed 
and the cells were washed with phosphate buffered saline (PBS). Trypsin/EDTA 
solution (Gibco) was added to the dish and the cells were agitated to make them 
slough off from the surface of the plate. After 2 minutes of incubation in 5% CO2 
incubator at 37°C�1ml of DMEM / F12 medium (Gibco) was then added to stop 
the trypsin reaction. The suspension was transferred into a snap-cap tube and 
centrifuged at ISOOrpm for 4 minutes at room temperature. The pellet was re-
suspended in DMEM / F12 medium (Gibco). After counting the cells, a 2 x 10^ 
cells suspension was added into new culture dish with 10ml DMEM / F12 
medium with 10% FBS (Gibco). 
2.1.2 Counting cells 
The cells were collected by adding trypsin/EDTA solution and centrifuged at 
1 SOOrpm for 4 minutes. The pellet was re-suspended in 1ml DMEM / F12 
medium (Gibco). 10|j.l of the re-suspended cells were mixed with 10 |j,1 of 1% 
Trypan Blue solution. The solution was pipetting up and down and 10 [x\ of the 
stained cells were filled into the grip of a hemacytometer. The cells were counted 
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within four comers of counting range and the central counting range. The density 
of cells was calculated by the following equation: 
D = ( N - 4 ) x 2 x 10^ 
(D = Cell density in cells/ml; N= Total no. of cells counted; Dilution factor = 2.) 
2.1.3 Retinoic acid differentiation 
The cells were seeded in 60mm and 100 mm culture dishes. The seeding density 
of SH-SY5Y cells was 1.2x10^ cells/ml and the volumes of medium for 60mm 
and 100mm culture dishes were 10 ml and 3 ml respectively. From day 1 after 
plating, cells were differentiated in the presence of 10 iiM all-trans-retinoic acid 
(RA) (Sigma) for five days. Cells were maintained at 37°C in an atmosphere 
containing 95% air and 5% CO2. 
2.2 Western blot analysis 
2.2.1 Extraction of protein from mammalian cells 
The SDS Lysis buffer was prepared freshly on the date of experiment. The 
components are shown in the following table: 
ImM Sodium Orthovanadate 100 pi 
ImM NaF 
IX Protease inhibitor 80 \x\ 
10/0 SDS 180 i^l 
H2O Add to 2000 yd 
Table 2.1: Components of lysis buffer for protein extraction 
The culture medium was removed and the plates were washed twice with IX PBS. 
For 6-well plate, 200 jil freshly prepared lysis buffer was added to each well to 
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lyse the cells. For 100mm plate, 500 |il freshly prepared lysis buffer was added to 
lyse the cells. The lysed cell samples were collected into individual Eppendorf 
tubes. The samples were then vortexed at 4°C for 10 minutes and centrifuged at 
HOOOrpm at 4°C for 10 minutes. The supernatant which contained the lysed 
proteins were transferred to new Eppendorf tubes. 
2.2.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
The Mini-Protein II electrophoresis cell (Bio-Rad) was used for SDS-PAGE. The 
gel-mould was assembled according to the manufacturer's instruction. Before 
adding gel solution, small amount of water was filled into the gel-mould to check 
for leaking. The 12% running gel solution was firstly prepared as shown in Table 
2.2. The running gel solution was poured into the gel-mould to 3/5 full. An 
amount of 150 [i\ of propanol was added on the top of the running gel solution 
surface to remove air bubbles and to keep the solution away from air. The gel was 
allowed to polymerize for 15-30 minutes at room temperature. The 4% stacking 
gel solution was prepared as shown in Table 2.2. After the stacking gel was 
poured into the remaining space, a comb was inserted into the layer of stacking 
gel solution, allowed the stacking gel to polymerize for 15-30 minutes at room 
temperature. The components of SDS-PAGE running gel and staking gel are 
shown in the following table: 
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12% Running gel Volume 4% Stacking gel Volume 
30% acrylamide solution 4 ml 30% acrylamide solution 1.3 ml 
1.5MTris-HCL, pH 8.8 2.5 ml 1.0 M Tris-HCL�pH 6.8 2.5 m l ~ 
10% SDS 100 [i\ 10% SDS 100 
Distilled H2O 3.4 ml Distilled H2O 6.1 ml 
10% APS 10% APS 5o7a 
TEMED I M TEMED 
Table 2.2: Components of SDS-PAGE running gel and staking gel 
The samples were denatured by adding loading dye and boiling at 100°C. The 
denatured samples and protein marker were loaded into the wells of the prepared 
SDS PAGE gel. The gel was run at a constant voltage of lOOV until the dye front 
reached appropriate distance. 
2.2.3 Semi-dry protein transfer to nitrocellulose membrane 
After performed SDS-PAGE, the gel was removed from the glass cassette set and 
removed away any stacking gel. The gel and nitrocellulose membrane were 
immersed in transfer buffer for 5 minutes, six pieces of filter paper were soaked 
into the transfer buffer for 30 seconds. In assembling the transfer stack, three 
pieces of wet filter papers was firstly placed on the cathode electrode plate, then 
the gel and nitrocellulose membrane was added respectively. Another three pieces 
of wet filter paper was placed on the top of the membrane. Finally, the anode 
electrode plate was placed on the top of the stack. The transfer stack was run at 
15V for 1.5 hours. 
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2.2.4. Membrane blocking and immunostaining 
After the proteins were transferred on the membrane, the membrane was washed 
in transfer buffer for 5 minutes. For Western Blotting analysis, the membrane was 
soaked into 10 ml blocking solution (IX TBS-T, 5% dry milk) 1 hour/ovemight, 
primary antibodies at 1:5000, 1:10000 dilution were added and incubated for 1 
hour. Afterwards, the membrane was then incubated with secondary antibodies 
(HRP anti-mouse, anti-rabbit antibodies) at 1:5000 dilutions in 10 ml TBS-T with 
5% dry milk for 1 hour. Finally, the membrane was washed for three times with 
IX TBST for 5 minutes. 
The immunoreactive protein bands in the blot were visualized by the ECL 
detection kit (Amersham). For signal detection, the solution 1 of the kit was 
mixed with solution 2 of the kit. The solution was added to the membrane that 
was placed on a piece of gradwrap. After 1-minute incubation, the excess solution 
was removed by blotting paper. The membrane was then covered with another 
piece of plastic Gradwrap and then placed in the X-ray film cassette with a X-ray 
film on the top. The film was usually exposed to the membrane for different time 
periods. If necessary, the membrane could be stripped and re-probed with other 
antibodies. 
The probes bound to the nitrocellulose membrane could be stripped off by 
incubating with strip buffer at 60 °C. The membrane is then blocked by 10 ml 
blocking solution (IX TBS-T, 5% dry milk) 1 hour/ovemight and other antibodies 
the stripped membrane is ready for probing with other antibodies. 
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2.3 MTT assay 
The SHSY-5Y cells were seeded in 96-well tissue culture plate. The number of 
the cells for each well was 3-5x1 O^  cells. To avoid evaporation, only central part 
of the plate (60 internal wells) was used. After differentiation, the cells were 
undergone drug treatment. After treatment, MTT solution (50 1 mg/ml) was 
added to each well and incubated for 3-4 hours. The formazan crystals were 
extracted from the cells with 150|al DMSO in each well. The colour was 
measured with 96-well ELISA plate reader at 550-570 run. 
2.4 Hoechst 33342 Nuclei staining 
The cells were seeded in 6-well plate with the seeding density 1.2x10^ cells/ml 
and the volume of medium for 6-well plate was 3ml for each well. After treatment, 
the old medium was discarded and the cells were washed with PBS twice. 0.5 ml 
PBS with lO^M Hoechst 33342 (Molecular probe) was added to the cells and the 
cells were incubated 15 min in the dark. The PBS with Hoechst 33342 was 
discarded and the cells were washed with PBS for one time. The stained nuclei 
were observed using the fluorescence microscope. 
2.5 Cell cycle analysis 
2.5.1 Ethanol fixation 
Adherent cells were trypsinized and collected from 60mm culture dishes. After 
centrifugation and washes with PBS twice at 4 the cells then finally collected 
by centrifugation. The cell pellet was then re-suspended in 1 ml ice cold 70% 
ethanol for overnight fixation at -20 
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2.5.2 Propidium iodide staining 
After fixation, the cells were then centrifuged and resuspended in 1 ml PBS. l|al 
10 mg/ml RNase (invitrogen) and 20 |LI1 Img/ml propidium iodide were added to 
the cells incubated at 37 for 30 mins. The DNA contents of the cells were 
determined in term of fluorescence intensity using FACSort flow cytometer 
(Becton Dickinson). Data obtained were analyzed using WinMDI 2.7 software 
(http://facs.scripps.edu，J. Trotter). 
2.6 Annexin V-FITC & Propidium iodide staining 
The adherent cells were trypsinized and collected from 60mm culture dishes. 
After centrifugion and washes with PBS twice at 4 the cells were then 
centrifuged to collect the cell pellet. The cell pellet was then re-suspended in IX 
binding buffer at 1 x 10^ cells/ml. An aliquot of 100 \x\ of the re-suspended cells 
(1 X 10^ cells) was transferred to a 5 ml culture tube. An amount of 5 \x\ 0.2|ag/|il 
annexin V-FITC (Santa cruz) and 10 |il 1 mg/ml propidum iodide (PI, Invitrogen) 
were added to the cells and incubated for 15 mins at room temperature in the dark. 
An amount of 400 [i\ of Ix binding buffer was added to the tube and the cells 
were analyzed in term of fluorescence intensity using FACSort flow cytometer 
(Becton Dickinson) within 1 hour. 
2.7 DNA fragmentation analysis 
2.7.1 Phenol/Chloroform extraction of DNA 
The cells were washed by PBS and lysed with the lysis buffer containing Tris-
HCL, SDS, EDTA and protease K and incubated at 37 overnight or 4 5 � C for 
2hours. An aliquot of 0.5 ml lysate was added to 1ml 
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phenol/chloroform/isopropanol mixture with a ratio of 25:24:1 by volume. The 
mixture was then mixed rapidly by vortexing and shaking at room temp for 10 
mins. After centrifugation at 12000rpm for 2 mins, the DNA containing aqueous 
layer was collected and transferred to a new tube and then ready for ethanol 
precipitation. 
2.7.2 Ethanol precipitation of DNA 
Two volumes of -20 absolute ethanol were added to the aqueous solution 
containing DNA. 50 [x\ 3M sodium acetate was added to the solution. The mixture 
was incubated at -20 °C overnight or -70 °C for 30 mins. Then the precipitated 
DNA was collected by centrifugation at 12000rpm for 10 mins at 4 The DNA 
pellet was washed by 70% ethanol at room temp. The DNA pellet was dried by 
air and dissolved in TE buffer. 
2.7.3 Agarose gel electrophoresis of DNA 
The isolated DNA was separated by 1.5% TBE agarose gel. The DNA sample 
was mixed with 6x gel loading buffer. After the gel was formed, it was put into 
the gel tank with TBE buffer just covering the gels. Then, the DNA samples were 
loaded into the gel and the electrophoresis was operated at constant V, 90V until 
the bromophenol blue dye front was migrated to desired distance. The gel can be 
visualized under UV illamination. 
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2.8 Proteomic analysis 
2.8.1 First dimension: isoelectric focusing 
The lysis buffer of protein extraction used in two dimensional 
electrophresis (2-DE) was different from western blotting. The components are 
shown in the following table: 
8M Urea 19.2 g 
4% CHAPS 
2% Pharmalyte (pH 3-10) 800 \i\ 
Double distilled H2O To 40 ml 
Table 2.3: The components of lysis buffer of protein extraction used in 2-DE 
The protein extraction followed the steps in 2.3.1. A commercial available 
13cm Immobiline™ DryStrips with pH 3-10 (IPG strips) (Amersham Biosciences) 
were used for first dimension isoelectric focusing. For 13cm long of IPG strip, 
250 |j.l rehydration buffer with 1.25 jal IPG buffer (Amersham Biosciences) and 
50 |il protein sample (40 |ag protein) were mixed and slowly added to the centre 
point in the slot of the IPGphor strip holder (Amersham Biosciences). Bubbles 
were removed in the solution mixture. The protective cover from the IPG strip 
was removed from the acidic (pointed) end. The IPG strip was positioned with the 
gel side down and was lowered onto the solution. After the IPG strip was placed 
in the IPGphor strip holder, the strip was overlaid with DryStrip Cover fluid. 
Then, the cover was placed on the strip holder to ensure that the IPG strip 
maintains good contact with the electrodes as the gel swells. The strip holder was 
properly positioned on the IPGphor platform. The pointed end of the strip holder 
was over the anode and the blunt end was over the cathode. The safety lid of the 
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platform was closed. Two of the three pressure pads under the safety lid pressed 
gently against the cover of strip holder to ensure contact between the electrodes 
and the electrode areas. lEF was performed using the following parameters: 0-
500V for 1 hour, 500-1000V for 1 hour, 1000-3000V for 1 hour, 3000-5000V for 
1 hour, 5000-8000V for 1 hour, and 8000V for 2 hours. After running the lEF, the 
strip was taken out and the cover fluid remained on the strip was removed by 
blotting on a piece of Scott blotting paper. Then, the strip was equilibrated in the 
equilibration solution (composition???) with DTT for 15 minutes. The strip was 
further equilibrated in the equilibration solution with iodoacetimdie (lAA) for 15 
minutes. 
2.8.2 Second dimension; SDS PAGE 
The Hoefer SE 600 vertical electrophoresis system (Amersham Pharmacia 
biotech) was used for second dimension SDS-PAGE. The gel-mould was 
assembled according to the manufacturer's instruction. Before adding gel solution, 
small amount of water was filled into the gel-mould to check for leaking. The 
12% running gel solution was firstly prepared as shown in Table 2.4. The running 
gel solution was poured into the gel-mould nearly full remaining small space for 
IPG strip. An amount of 300 \x\ of butanol was added on the top of the running gel 
solution surface to remove air bubbles and to keep the solution away from air. 
The gel was allowed to polymerize for 15-30 minutes at room temperature. The 
components of second dimension SDS-PAGE running gel is shown in the 
following table: 
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12% Running gel Volume 
30% acrylamide solution 16 ml 
1.5MTris-HCL, pH 8.8 ~ 
10% SDS 400 111~ 
Distilled H2O 13.6 ml 
10% APS 200 I I I ~ 
TEMED 407ii 
Table 2.4: Components of second dimension SDS-PAGE running gel 
The equilibrated strip was placed into the top of prepared second dimension SDS-
PAGE running gel. Protein marker was added to the left of the gel. Then agarose 
sealing solution was added to the remaining space. The gel was run at a constant 
voltage of 1OOV until the dye front reached appropriate distance. 
2.8.3 Gel staining 
2.8.3.1 Silver staining 
Silver staining kit from Amersham Biosciences was used for detection of proteins 
on the 2-DE gel. For fixing the gel, 100ml of silver staining fixing solution was 
added to a glass box with the gel inside for 2hours or overnight. After fixing, the 
fixing solution was removed and 100ml of sensitizing solution was added to the 
box for sensitizing the gel. After that, the sensitizing solution was removed and 
the gel was washed with 100ml distilled water for 5 minutes three times. Then, 
100ml silver solution was added to the gel for 30 minutes. Again, the gel was 
washed with 100ml distilled water for 1 minutes 2 times. 100ml of developing 
solution was added to the gel and removed until the appearance of most protein 
spots. To stop the reaction, 100ml stopping solution was added to the box for 10 
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minutes. The gel was preserved in 100 ml preserving solution for gel scanning 
and protein spots were excised from the gel for further analysis. 
2.8.3.2 SYBRO Ruby staining 
SYBRO ruby staining from Molecular Probes was the fluorescence dye used for 
detection of proteins on the 2-DE gel. For fixing the gel, 100ml of fixing solution 
was added to a glass/plastic box with the gel inside for 2 hours or overnight. After 
fixing, the fixing solution was removed and 100 ml of SYBRO Ruby dye was 
added to the box for staining overnight. After that, the staining solution was 
removed and the gel was washed with 100ml distilled water for 30 minutes twice. 
2.8.4 Gel scanning and image analysis 
The silver-stained 2-DE gels were digitalized using a flatbed scanner at 300dpi 
(Amersham Bioscience) while the SYBRO Ruby-stained 2-DE gels were scanned 
by Typhoon laser scanner (Amersham Bioscience). The image data were analyzed 
by Image master 2D platinum Software (Amersham Bioscience). In order to 
eliminate the individual variations on 2-DE patterns, three spots pairs appearing 
in same positions on two gels were picked up, yielding landmarks for the gels. 
Then the gels were overlapped according to the positions of the landmarks. Spots 
on each gel were paired according to their positions. Spot volume (VOL) was 
defined as the integration of optical density (OD) over the spot's area, while 
relative volume (%VOL) of a given spot was the ratio of VOL to total VOL over 
the whole image. Therefore, the effect of the fluctuation in the gel staining density 
can be minimized by comparing the %VOL of each spot. The %VOL of the spots 
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was analyzed to detect specific spots showing significant differences between 
control and after drug treatment. 
2.8.5 In-gel digestion 
Protein spots were excised and cut into smaller pieces with surgical needle and 
placed into Eppendrof tubes. For silver stained-protein spots, 10 pi Potassium 
Ferricyanide (30 mM) and 10 |il Sodium thiosulphate (lOOmM) were added to 
each Eppendrof tubes. The Eppendrof tubes were vortexed until the dark stain 
was removed and the protein spots were washed with autoclaved nano-water. For 
those SYBRO Ruby-stained protein spots, the de-staining step could be omitted. 
Then, the protein spots were equilibrated in 20 jil Ammonium bicarbonate 
(200mM) for 10 minutes and then washed with nano-pure water. The washing and 
equilibration procedures were repeated once. After equilibration, the protein spots 
were dehydrated with 100 jal acetonitrile for 10 minutes for three times. Then, the 
protein spots were dried in the speed vacuum for 2-5 minutes until the protein 
spots became 'dust like'. The protein spots were rehydrated with 10 jil trypsin 
enzyme in buffer (40ng/|jl trypsin in 50mM Ammonium bicarbonate) and 
incubated on ice for 30 minutes. After that, enough buffer solution (50mM 
Ammonium bicarbonate) was added to cover the hydrated protein spots at 30 
overnight. After digestion, the proteins in the protein spots were extracted by 
adding 20 |j.l 50mM Ammonium bicarbonate to the Eppendrof tubes and the 
protein digests were sonicated for 10 minutes. The protein spots were spun down 
and the supematants were transferred to new Eppendrof tubes. An amount of 10 
Acetonitrite and 10 \i\ 5% TFA was added to the Eppendrof tubes and the 
protein spots was sonicated for 10 minutes. Again, the supematants were 
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transferred to the new Eppendrof tubes. This step was repeated three times. Lastly, 
10 pi Acetonitrile was added. After sonication, the supernatant was transferred to 
the tubes again. The supernatant extract was dried with speedy vacuum to obtain 
the protein sample. 
2.8.6 Zip Tip for desalting the digested sample 
TheZipTipClS microcolumn (Millipore) was used to desalt and concentrate the 
protein samples. The vacuum-dried protein samples were resuspened in 10 |il 
0.1% TFA. The ZipTip was wet by aspirated 10 |il 50% acetonitrite into the tip 
and dispensed to waste two times. An amount of 10 [ol equilibrium solution (0.1% 
TFA) was aspirated into the tip and dispensed to waste two times. The sample 
was bound into the ZipTip by aspirated and dispensed 10 cycles in the Eppendrof 
tube containing resuspened protein sample. The ZipTip with the protein sample 
bound was washed by 10 |il 0.1% TFA by aspirated and dispensed into waste 5 
times. The protein sample was eluted with 2 |j.l 50% acetonitrite / 0.1 % TFA in a 
new 0.5ml tube by aspirated and dispensed 5 times. 
2.8.7 Protein identification with mass spectrometry and database search 
The MALDI-TOF mass spectrometry was performed on ABI4700 proteomic 
Analyzer equipped with 200Hz solid-state laser (Applied Biosystems). The 
MALDI-TOF mass spectrometer was operated in positive-ion, delayed extraction 
(150ns delayed time), and reflector mode. Trypsin autocleavage peaks were used 
as internal standard for mass calibration. The mass spectrometry peaks were 
analyzed with Data Explore software that is based on Mascot search engine to 
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identify the proteins. The masses of all the tryptic peptides were queried on the 
SwissProt and NCBInr protein databases. 
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Chapter 3: Characterization of Okadaic acid-induced tau 
hyperphosphorylation in SH-SY5Y cells 
3.1 Introduction 
Alzheimer's disease (AD) is characterized by neuronal cell loss and several pathologic 
hallmarks, e.g. amyloid plaques deposits and neurofibrillary tangles (NFT) (Vickers et 
al., 2000). It has been shown that the amount of NFT correlates closely with the degree 
of dementia NFT are composed of abnormally hyperphosphorylated microtubule-
associated protein (MAP) tau (Arriagada et al., 1992). Tau, mainly expressing in 
neuronal axons, is phosphorylated at very low level in normal adult brain 
Hyperphosphorylated tau fails to bind microtubules, leading to disassembly of 
microtubules, disruption of axonal transport, and ultimately leading to 
neurodegeneration (Iqbal et al., 2000). 
Regulation of tau phosphorylation by protein kinases (PKs) and protein phosphatases 
(PPs) maintains dynamic balance of phosphorylation state of tau under normal 
physiological conditions. Normal tau can be phosphorylated by many kinases, such as 
glycogen synthase kinase (GSK)-3a and -3p，cyclin-dependent kinases 5 and mitogen-
activated protein kinase (MAPK). The tau dephosporylation is regulated by protein 
phosphatise, such as phosphatase 2A and phosphatase 2B. Thus, the dephosphorylation 
activity of PP is necessary for keeping tau at low phosphorylated level and with normal 
biological functions (Kins et al., 2001). The PP activity has been reported to be reduced 
by about 30% in AD brain compared to control (Gong et aL, 1995). This implies that 
the defect of PP activity is closely related to the abnormally hyperphosphorylation of 
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tau which may then contribute to the disassembly of microtubules, disruption of axonal 
transport and neurodegeneration. 
Okadaic acid is a complex polyether derivative of a 38-carbon fatty acid. It is 
synthesized by marine dinoflagellates and accumulates in filter feeding organisms such 
as shellfish or the black sponge (Tachibana et al., 1981). Okadaic acid is harmful to 
human health due to its ability to cause diarrhetic shellfish poisoning. It can inhibit 
certain members of the serine/threonine protein phosphatase family, including PPl, 
PP2A and PP2B by binding to the catalytic subunit for enzymatic activity inhibition 
(Bialojan and Takai, 1988). Because of its inhibition of phosphatase activity, okadaic 
acid quickly became a tool to investigate the cellular functions of the respective 
okadaic acid-sensitive phosphatases (Schonthal, 1992). 
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3.2 Objectives 
Since abnormal hyperphosphorylation of the microtubule-associated protein tau is a 
key pathologic molecular change correlated to the neurodegeneration in Alzheimer's 
disease brain, thus this study is aimed at establishing an okadaic acid-induced apoptosis 
cell line model that can be used to search for any potential flavonoids against tau 
hyperphosphorylation and cell death. Before flavonoids screening, the cell model was 
characterized to examine whether it can mimic some molecular or morphological 
changes in Alzheimer's disease affected neurons. The molecular changes included 
phosphorylated tau protein level, apoptotic and anti-apoptotic protein level e.g. caspase 
3 and Bcl-2. And also the morphological change was observed, e.g. neurite retraction 
and nucleus condensation. Moreover, the apoptosis and cell death after OA treatment 
was also measured by using flow cytometry. 
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3.3 Results 
3.3.1 Differentiation of SH-SY5Y cell 
SH-SY5Y is a human neuroblastoma cell line with two cell phenotypes which are 
neuroblastic phenotype (N—type) and substrate adherent phenotypes (S-type).After the 
retinoic acid treatment, the N-type cells will become differentiated and the S-type cell 
will undergo apoptosis. Undifferentiated SH-SY5Y cells exhibited roundish features 
initially (Figure 3.1 A). Treatment with 10|aM RA for 5 days induced neuronal 
differentiation resulting in cells that acquired a more neuron-like phenotype and signs 
of neurite outgrowth (Figure 3.IB). 
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Fig. 3.1: The human neuroblastoma SH-SY5Y cells were differentiated into 
neuron like cells with more neurite outgrowth. (A) Undifferentiated SHSY-
5Y cells exhibited roundish shapes with few neurite outgrowth. (B) Retinoic acid 
induced neuronal differentiation with the loss of round morphology and signs of 
neurites outgrowth. Cells were visualized using phase contrast microscopy 
(200X). Bar = 25 |im. 
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3.3.2 Changes of protein expression after okadaic acid treatment 
After differentiation, the cells exhibited an extensive neurite outgrowth. These cells 
were incubated with DMSO (control), lOnM, 25nM, 50nM, lOOnM okadaic acid (OA) 
and 0.5|aM staurosporine (STS) for 18 hours. For detecting tau phosphorylation, PHF 
ATS antibody was used. This antibody recognizes paired helical filament with 
phosphorylated tau at site Ser202 which is one of the dephosphorylation site regulated 
by protein phosphatase 2A. Since it can recognize different tau isomers, several bands 
were detected due to the different sizes of the isomers. After okadaic acid treatment, 
tau phosphorylation increased in dose-dependent manner and there was no tau 
phosphorylation after treatment of another apoptosis inducer-staurosporine (Fig. 3.2A). 
Caspase-3 is an apoptotic enzyme, which is first synthesized as inactive pro-enzyme 
with the size 35-kDa. After activated by the cleavage of caspase-8 or caspase 9, the 
active fragment of caspase 3 with the sizes 17-kDa can cleave other protein substrates 
within the cell, resulting in the apoptotic process�e.g. DNA ladder formation. After 18 
hours OA treatment, both the expression of pro and active forms of caspase 3 increased 
with the OA concentration. There was also increase of pro and active forms of caspase 
3 after staurosporine treatment (Fig. 3.2B). Bcl-2 is an anti-apoptotic enzyme with the 
size 25-kDa, which governs mitochondrial membrane permeabilisation. It can inhibit 
the release of cytochrome C to activate caspase cascade. The western blot showed that 
the Bcl-2 protein level increased after okadaic acid treatment and peaked at lOOnM OA 
treatment (Fig. 3.2C). 
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Fig. 3.2: Changes of protein expression after okadaic acid treatment. Western 
blots of SH-SY5Y cell extracts prepared from the cells that had been treated with 
different concentrations of okadaic acid (OA) and 0.5|iM Staurosporine (STS) for 
18 hours were labeled with antibodies to (A) PHF-AT8 tau, (B) Pro- and Active-
form of caspase 3，(C) Bcl-2. GAPDH immunoblot was used as constitutive protein 
control to normal protein loading in each sample. The results were repeated with 
two independent treatments (n=3). 
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3.3.3 Neurite Retraction Induced by okadaic acid 
Since hyperhosphorylated tau fails to bind microtubules, the microtubules will be 
destabilized and disassembled, thus neurite retraction of the neurons will be observed. 
After okadaic acid and staurosporine treatments, the morphologies of SHSY-5Y were 
shown as Figure 3.3. When the concentration of okadaic acid increased, more cells 
suffered from neurite retraction and became roundish shapes. At 50nM OA treatment 
(Fig. 3.3D), most cells exhibited roundish shapes with few neurite outgrowths and cell 
death occurred obviously at lOOnM OA treatment (Fig.3.3E). However, compared to 
another cell death inducer, staurosporine (STS) induced cell death of the cell but the 
neurite of the cells remained without retraction (Fig.3.3F). 
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Fig. 3.3: Neurite retraction induced by okadaic acid in a dose dependent manner. 
Differentiated Cells were incubated with different concentrations of (A-E) okadaic acid 
(OA) and (F) 0.5iaM Staurosporine (STS) for 18 hours. Cells were visualized using 
phase contrast microscopy (lOOX). Bar = 50|am. 
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3.3.4 Okadaic acid-induced Cell Death measured by MTT assay 
The cell death induced by okadaic acid was measured by the MTT assay. The SHSY-
5Y cells were seeded in 96-well culture plate at a density of 4x10"^  cells for each well 
and then differentiated by lO^iM retinoic acid. Cells were then treated with various (10-
100 nM) concentration of okadaic acid for 18 hours and the MTT assay was performed 
to measure the cell viability. Figure 3.4A showed that survival percentage greatly 
decreased to 60% at 50nM okadaic acid and dropped to 11% at lOOnM while there was 
less cytotoxic effect at lower okadaic acid concentrations. The cell death induced by 
okadaic acid at different time periods was also investigated. Figure 3.4B showed that 
survival percentage greatly decreased to 58% at 18 hours treatment and dropped to 
13% at 24 hours treatment while there was less cytotoxic effect at 0, 2, 4, 6 hours 
treatments. 
3.3.5 Hoechst 33342 Nuclei Staining 
Hoechst 33342 is a fluoresence dye that can bind preferentially to A-T base-pairs of 
DNA. When the cell undergoes apoptosis, it will have condensed and fragment nuclei, 
with higher fluoresence intensity compared to the normal cells. Figure 3.5 showed the 
Hoechst 33342 nuclei staining after okadaic and staurosporine treatment. In control, 
there were few numbers of apoptotic nuclei showing bright blue fluoresence and most 
cells were attached on the culture plate (Fig.3.5A). However, the number of apoptotic 
nuclei increased with the OA concentrations and more cells were detached from the 
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Fig. 3.4; Cytotoxic effect of Okadaic acid in differentiaed SH-SY5Y cells. (A) 
Cells were incubated with different concentrations of Okadaic Acid for 18 hours. 
Cell death was quantified by MTT assay measuring the mitochondria activity. (B) 
Cells were incubated with 50 nM Okadaic Acid in different time periods. Cell death 
was quantified by MTT assay. Data were mean 土 SEM (bars) values of three 
independent experiments 
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A. Control (DMSO) B. 10nM OA • • 
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Fig.3.5: Increase of fragmented and condensed nuclei by Okadaic acid in a dose 
dependent manner. Differentiated Cells were incubated with different 
concentrations of okadaic acid (OA) and 0.5|iM Staurosporine (STS) for 18 hours, 
then the cells were stained with Hoechst 33342 dye and examined by fluorescence 
microscope (lOOx) for morphological change. Bar = 50|a,m. 
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3.3.6 Cell cycle analysis by propidium iodide staining 
To investigate the apoptotic effect of okadaic acid, cell cycle analysis by flow 
cytometry was studied. Propidium iodide was used as the fluorescence dye for the 
analysis. PI can bind to the major groove of double strand DNA. The intensity of the 
fluorescence can reflect the DNA content of cells. During apoptosis, the genomic DNA 
is cleaved by endonuclease to form DNA fragments. After fixation, the DNA fragments 
may leak out due to permeabilisation of cell membrane and the cells contain less DNA 
content and thus fluorescence intensity of the cells decreases. Figure 3.6 showed the 
histograms representing the number of events (cells) against PI intensity-area (i.e. 
DNA contents) after okadaic acid treatment. Table 3.1 summarized the percentage of 
cells with different DNA contents representing different cell cycle stages of the cells. 
Okadaic acid increased apoptotic cells in a dose dependent manner. The apoptotic sub 
G1 cells that were sub-diploid rose from 3.4% (Control: DMSO) to 18% (lOOnM OA). 
However, the diploid GO/Gl cells decreased from 90% (Control: DMSO) to 80% 
(lOOnM OA). For S and G2/M cells, they decreased from 5.41% (Control: DMSO) to 
2.38-0/0 (lOOnM OA). 
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Fig. 3.6: Flow cytometry analysis of Okadaic acid-induced apoptosis using 
propidium iodide (PI) staining. Cells were incubated with different concentrations 
of Okadaic Acid for 18 hours and stained with propidium iodide. After staining, the 
DNA contents of cell populations were analyzed by flow cytometer. 
Apoptotic 
Sub Gi Go, Gi S, G2/M 
Con (DMSO) 3.42% 90.82% 5.41% 
25nM OA 5.04% 91.58% 3.31% 
SOnM OA 12.53% 83.46% 4.36% 
lOOnM OA 18.07% 80.12% 2.38% 
Table 3.1: Percentage of cells in different cell phases after okadaic acid 
treatment. The percentages of cells were calculated by the size of areas at different 
phases in the PI intensity-area histogram plot. 
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3.3.7 Early Apoptotic cells detection by Annexin V/PI staining 
For annexin V/PI staining, it can monitor the early stage of apoptosis. When the cell 
begins apoptosis, the membrane protein: phosphatidylserine (PS) will translocate from 
inner to outer membrane and become available for annexin V. However, if the cell is at 
late apoptosis or necrosis, apart from annexin binding, the PI can also penetrate into the 
cell and bind to nuclei acid. 
Figure 3.7 showed that after OA treatment, the normal cells shifted from left bottom 
region (I) to right bottom region II (Pl-negative/Annexin-V positive) and right upper 
region III (Pl-positive/Annexin-V positive). The percentage of normal cells decreased 
from 90% (Control: DMSO) to 58% (lOOnM) while the apoptotic cells increased from 
3.7% (Control: DMSO) to 32% (lOOnM). The number of late and necrotic cells slightly 
increased from 4.75% (Control: DMSO) to 8.67% (lOOnM). 
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Fig. 3.7: Flow cytometry analysis of early apoptotic cells after OA treatment. Cells 
were incubated with different concentrations of Okadaic Acid for 18 hours and stained 
with Annexin V with propidium iodide. After staining, the cell populations were 
analyzed by flow cytometer. Data from 10,000 cells were analyzed for the experiment. 
Region I: Pl-negative/annexinV-negative, Region II: Pl-negative/ annexinV-positive, 
III: Pl-positive/ annexin V-positive 
I. Normal II. Apoptotic III. Necrotic 
Con (DMSO) 90.06% 3.75% 4.75% 
lOnM OA 78.95% 15.67% 5.85% 
25nM OA 88.16% 4.59% 3.87% 
50nM OA 90.06% 6.12% 3.08% 
lOOnM OA 58.15% 32.85% 8.67% 
Table 3.2: Percentage of cells in different cell stages after okadaic acid treatment. 
The cells were quantifed as the percentage of the total cell population at different 
regions. 
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3.3.8 DNA fragmentation 
At the late stage of apoptosis, the inhibitor of caspase-activated DNase (ICAD) will be 
cleaved by Caspase-3 to become caspase-activated DNase (CAD), which can cleave 
the genomic DNA into about 200 base pairs DNA fragments. Figure 3.8 showed that 
the DNA from the differentiated SH-SY5Y cells treated with lOOnM OA resulted in a 
ladder-like pattern of DNA fragmentation with characteristic fragments separated in 
size by approximately 200 base pair while the Control, lOnM OA, 25nM OA, 50nM 
OA treatments did not showed DNA fragmentation. For 0.1 jxM staurosporine and 
O.SjiM staurosporine treatment, they represented the positive controls of this 
experiment, which showed a clear DNA ladder pattern. 
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Fig. 3.8: DNA fragmentation in Differentiated SH-SY5Y cells treated with 
Okadaic acid. DNA was extracted from DMSO- or OA-treated cells and subjected 
to agarose gel electrophoresis. DNA ladder formation was observed in 100 nM OA 




Neurodegeneration characterized by accumulation of hyperphosphorylated tau and 
formation of neurofibrillary tangles (NFTs) is a hallmark in Alzheimer's disease (AD) 
(Grundke-Iqbal et al., 1986). Studies on AD brains have demonstrated that abnormally 
hyperphosphorylated tau is the major protein subunit of NFT (Lee et al, 1991), which 
suggests that hyperphosphorylation of tau may play a role in leading the neuronal cells 
to undergo apoptosis. Tau is a microtubule-associated protein, which the major function 
of tau is to promote microtubule assembly and stabilize microtubules formation. The 
accumulation of tau hyperphosphorylation in the development of neurofibrillary 
degeneration was observed in the AD brains (Grundke-Iqbal et al., 1986). 
It has been shown that during Alzheimer's disease, some neurons in the AD brain 
showed characteristics of programmed cell death, which contributed to neuronal cell 
loss observed during the progression of the disease (Su et al., 1994). The characteristics 
of programmed cell death or apoptosis include changes of apoptotic and anti-apoptotic 
protein level e.g. caspase 3 and Bcl-2. Moreover, cell shrinkage, plasma membrane 
blebbing, nuclear chromatin condensation and DNA fragmentation morphological 
change were also found during apoptosis. 
Tau hyperphosphorylation is due to the imbalance of kinase and phosphatase activites. 
In this study, okadaic acid (OA), a protein phosphatase inhibitor, was chosen to induce 
tau hyperphosphorylation by reducing the phosphatase activities. Okadaic acid can 
inhibit different phosphatase but the IC50 varies greatly among the phosphatase. When 
cells were treated with okadaic acid at nanomolar concentration, the major cellular 
effects are contributed to the inhibition of PP2A. However, if the concentration 
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increases to micromolar level, several protein phosphatases can be inhibited effectively, 
e.g. PPl and PP2A. 
From the western analysis, PHF-tau phosphorylation was increased in a dose dependent 
manner after OA treatment, which is detected by PHF-tau ATS antibody. This antibody 
recognizes paired helical filament with phosphorylated tau at site Ser202 which is one 
of the dephosphorylation site regulated by protein phosphatase 2A. This showed that 
OA can inhibit phosphatase 2A to induce tau phosphorylation. Moreover, both the pro 
and active forms of caspase 3 were also increased. This showed that OA can induce the 
expression of pro-caspase 3 and the level of active form of caspase 3 to promote the 
apoptotic process. Anti-apoptotic protein Bcl-2 was also increased significantly at 
50nM and lOOnM OA treatment, suggesting that the toxicity and stress of OA may 
induce a protective mechanism of the cells, which was observed at the neurons in 
Alzheimers disease patients. Apart from okadaic acid, staurosporine, an apoptosis 
inducer, was used to serve as a positive control. Unlike okadaic acid, treatment of cells 
with staurosporine did not show an increase in tau phosphorylation but showed a 
slightly increase of pro and active forms of caspase3 and Bcl-2 levels. This data 
suggested that the cell death or apoptosis could be induced with or without tau 
phosphorylation. 
Okadaic acid inhibits PP2A activity and induces tau hyperhosphorylation which leads 
to neurite retraction of the neurons due to the destabilization and disassembly of 
microtubules. As demonstrated in this study, okadaic acid caused neurite retraction 
and cell death whereas staurosporine didn't induce the neurite retraction but exhibited 
cytotoxic effect on the cells. These findings indicated that the neurite retraction was not 
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a phenomenon of cell death but probably caused by destabilization of microtubules due 
to the tau hyperhosphorylation induced by okadaic acid. A measure of cell viability by 
MTT assay based on mitochondrial activity showed that OA can induce cell death at 
high concentrations and long incubation times. Moreover, the condensed and 
fragmented nuclei were observed by the Hoechst 33342 staining after OA treatment, 
suggesting that OA induced cell death through apoptosis. 
For the cell cycle analysis by PI staining, the apoptotic effect of OA on the SH-SY5Y 
cells was measured by analyzing the DNA content of the cells which represent different 
cell stages. The results showed that the apoptotic sub G1 cells increased gradually 
when the concentration of OA rose up. However, the Gl/GO�S and G2/M cells were 
reduced after OA treatments. For the annexin V/ PI staining, it is a sensitive method to 
measure the percentages of cells undergoing apoptosis or necrosis. The results showed 
that the apoptotic cells increased after OA treatment while the necrotic cells didn't 
change. And the DNA fragmentation assay also showed that the DNA ladder pattern 
was observed at lOOnM OA treatment. These results suggested that the cytotoxic effect 
of OA was through the apoptosis mechanism, which is also the main mechanism of cell 
dying in Alzheimer disease. 
In summary, OA treatment of neuroblastoma cells appears to mimic the characteristics 
of cellular and biochemical changes associated with tau hyperphosphorylation-induced 
neuronal cell death of Alzheimer's disease. OA treatment caused an increase in PHF 
tau protein formation, leading to the activation of capase-3 mediated apoptotic cell 
death. This cell model was being exploited to examine the neuroprotective effects of 
flavonoids. 
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Chapter 4: Flavonoids screening for protecting neuronal death by 
preventing tau hyperphosphorylation 
4.1 Introduction 
The flavonoids are a group of polyphenolic compounds widely distributed in the 
plant kingdom. More than 6400 flavonoid compounds have been discovered 
contributing to the flavor and pigment of the fruits and vegetables. Flavonoids 
have important roles in plant growth, reproduction, and pathogen resistance 
(Harbome and Williams, 1992). Flavonoids are polyphenolic compounds which 
are rich in many foods in our diet, for example, tea, coffee, chocolate, and wine. 
A well-balanced diet with the recommended daily servings of fruits and 
vegetables and moderate amounts of tea, coffee, wine, beer, or chocolate can 
provide well over 1000 mg of total polyphenols and flavonoid per day (Lotito and 
Frei, 2006). 
Many studies have found that flavonoids can protect brain aging and some 
neurodegenerative disease. Normal brain aging is associated with elevated levels 
of reactive oxygen species (ROS) and neuroinflammation. ROS are the by-
product of normal metabolism, which can give rise to oxidative cellular damage. 
Our brain is especially susceptible to oxidative stress because the brain utilizes 
20% of the total oxygen consumption, causing a large production of ROS. It has 
been found that inflammation of the brain results in the activation of the 
protecting microglial cells to produce high level of ROS and cytokines. There is 
evidence that increased oxidative stress plays an important role in the 
pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD) and 
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Parkinson disease (PD). Flavonoids have been found to have potent antioxidant 
and free radical scavenging activities in vitro (Halliwell, 2007). Thus, it has been 
proposed that flavonoids can relieve oxidative stress and neuroinflammation, 
which may protect the brain from developing neurodegenerative diseases. Apart 
from reducing oxidative stress and neuroinflammation, flavonoids have also 
involved in many mechanisms against beta-amyloid-induced toxicity (Han et al, 
2004) and in promoting neurogenesis (Casadesus et al, 2004). 
4.2 Objectives 
In the previous study (Chapter 3), an okadaic acid (OA)-induced neuronal apoptosis 
cell model has been established and characterized. In light of the great potential of 
flavonoids in protecting neuronal cells from apoptosis which can be further exploited 
as therapeutic agents to treat neurodegenerative diseases, the effects of flovonoids to 
protect against OA-induced neuronal cell apoptosis are being examined. OA is found to 
induce tau protein hyperphossphorylation, neurite retraction, capase-3 activation and 
nuclear condensation of SH-SY5Y cells leading to apoptotic cell death. In this study, 
approximately 32 flovonoids and pure compounds have been screened for their ability 
to protect OA-induced tau hyperphosphorylattion, caspase 3 activation, neurite 
retraction, nucleus condensation. 
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4.3 Tested flavonoids 
Morin, chyrsin, quercetin, rutin, baicalein, (+)-catechin, huperzine, hesperidin and (-)-
epicatechin were purchased from Invitrogen. Naringin, baicalin, silybin, fererol, 
luteolin, scutellarin, wogonin, apigenin, tangeretin, icariin, kaempferol, casticin, 
daidzein, daidzin, formononetin, genistein, genistin, glycitein, glycitin, puerarin, 
cardamonin, phloretin and sulphuretin were generous gift from Dr. Tsim Lab. (The 
Honk Kong University of Science and Technology). The purities of these flavonoids 
were over 90% and they were dissolved in dimethyl sulfoxide (DMSO) to give stock 
solutions at concentration of 1 OOmM. 
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4.4 Results 
4.4.1 Toxicity of flavonoids 
In view of some flavonoids have previously been reported to have cytoxicity in cancer 
cells, the effects of these compounds were tested by MTT assay Figure 4.1 showed 
that at a concentration of 5 [iM, these flavonoids did not produce significant 
cytotoxicity to the SH-SY5Y cells. 
5 9 
1 2 0 — 
1 � � - n … --士T T ' f r . n n - r ; -云汗 --…sfl-p^-;：…Hfr fe-：;…FH. 
咨 90 - .5-0.-0.….…m••…再 口-再-�…口-百 aifl……. 
0) n 
D： 8 0 -







0 ~丨• 11 •• I •丨丨• I I 11 I •丨 I • I I •丨丨 I" I 丨丨• 111" I 丨 I • I 丨• 11 •丨 11111111 丨 11 丨 111 I •丨 11 丨 1111 丨丨 111 111 I • I I • 111 丨 I _ I 11 丨 
C C C C C C C C D ^ C C C - o C C C C C C o C C C C C C C C C C C C C 
1 1 1 ^ 1 s ^ 1 1 1 i 1 2 i 1 1 1 
… p f } 1 塌 | i 购 p t | 
Fig. 4.1: Cytotoxicity test of the flavonoids on differentiated SH-SY5Y cells. 
Differentiated Cells were incubated with SjiM Flavonoids 24 hours. Cell death was 
quantified by MTT assay measuring the mitochondria activity. Percentage of cell 
survival compared to control was calculated. Data were mean 土 SEM (bars) values 
of three independent experiments. 
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4.4.2 Effects of flavonoid pre-treatment on OA-induced neurite retractions and 
cell death 
As shown in previous study, one of the observable effects of OA on neumal cells is the 
retraction of neurite outgrowth, suggesting OA disrupts the cytoskeletal structure of 
neuronal cells (Fig. 4.2B). In order to examine whether flavonoid pre-treatment could 
prevent neurite retraction, cells were treated with 5}iM flavonoids for 24 hours 
followed by the induction of cell apoptosis by OA (50 nM) treatment. The 
representative results were shown in Fig 4.2 C-F. None of the 32 flavonoids examined 
here is able to reverse the neurite retraction induced by OA 
The ability of flavonoid to protect OA-induced cell death was also examined. The cell 
viability was measured by the MTT assay. Cell cultures treated with 50 nM OA for 18 
hours caused approximately 37.5% cell death compared to the control cultures. Pre-
treatment of the cells with various flavonoids failed to show any protection of the cell 
death induced by okadaic acid. Casticin, for example, was found to enhance slightly the 
cytotoxic effect of OA, causing a significant 60% cell death in the cultures. 
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A. Control (DMSO) B. 50nM OA 
C. 5|jM Quercetin + SOnM OA D. SPM Rutin + 50nM OA 
• ： ：： r . 
. •  ” ——'：、�、、：：.，>! 
E. 5mM (+)-Catechin + SOnM OA F. 5jjM Hesperidin + SOnM OA 
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Fig. 4.2: Pre-treatment of flavonoids on OA induced neurite retractions in SH-
SY5Y cells. Differentiated SH-SY5Y cells were pre-incubated with flavonoids for 
24 hours, followed by the inclusion of 50nM OA in the cultures, After 18 hours of 
incubation, cells were examined using phase contrast microscopy (lOOX). The 
representative figures pretreated with quercetin (C), rutin (D), (+)-Catechin (E) and 
hesperidin (F). Bar = 50 \im 
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Fig. 4.3: Effects of pre-treatment of flavonoids on OA-induced cell death. 
Differentiated Cells were incubated with 5|iM Flavonoids 24 hours in addition to 
50nM OA 1 Shours. Cell death was quantified by MTT assay measuring the 
mitochondria activity. Percentage of cell survival compared to control was 
calculated. Data were mean 土 SEM (bars) values of three independent 
experiments. 
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4.4.3 Western blot analysis 
In order to investigate whether flavonoids exhibits neuroprotective effect on the dying 
cells induced by OA or not, the Western blot analysis was performed to measure the 
change of several protein expressions, i.e. phosphorylated tau at site Ser202, pro and 
active forms of caspase 3 and Bcl-2 proteins. After OA treatment, tau phosphorylation 
increased since OA inhibited the PP2A dephosphorylation activity. When the cells 
were treated with 5|aM flavonoids in addition to SOnM OA treatment, several 
flavonoids showed the ability to reduce the tau hyperphosphorylation at site ser202. 
These flavonoids included hesperidin (8)，fererol (12), genistin (25) and glycitein (26) 
(Fig. 4.4). Many flavonoids were found to reduce the levels of both pro and active 
forms of caspase 3. These flavonoids included (+)-catechin (6), huperzine (7), 
hesperidin (8), fererol (12)，luteolin (13)，wogonin (15), apigenin (16)，tangeretin (17) 
and icariin (18) (Fig. 4.5). The anti-apoptotic protein- Bcl-2 was found significantly 
increased after OA treatment, probably due to a feedback protective regulation in 
response to OA toxicity. Many flavonoids were found to increase the levels of Bcl-2. 
These included (+)-catechin (6), huperzine (7), hesperidin (8), luteolin (13), scutellarin 
(14), tangeretin (17). 
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Fig. 4.4: Effects of flavonoids pre-treatment on OA-induced 
hyperphosphorylated tau expressions. The differentiated SH-SY5Y cells were 
pretreated with 5uM flavonoid for 24 hours, followed by 50nM okadaic acid for 
18 hours. Cell lysates were prepared for Western blots against antibodies to PHF-
AT8 tau (Ser202). GAPDH immunoblot was used as constitutive protein control 
to normal protein loading in each sample. The results were repeated with one 
independent treatment (n=2). 
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Fig. 4.5: Effects of flavonoids pre-treatment on OA-induced Pro and Active 
forms of caspase 3 expressions. The Differentiated SH-SY5Y cells were 
pretreated with 5uM flavonoid for 24 hours, followed by 50nM okadaic acid for 
18 hours. Cell lysates were prepared for Western blots against antibodies to Pro-
and Active-form of caspase 3. GAPDH immunoblot was used as constitutive 
protein control to normal protein loading in each sample. The results were 
repeated with one independent treatment (n=2). 
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Fig. 4.6: Effects of flavonoids pre-treatment on OA-induced Bcl-2 expression. 
The differentiated SH-SY5Y cells were pretreated with 5uM flavonoid for 24 
hours, followed by 50nM okadaic acid for 18 hours. Cell lysates were prepared for 
Western blots against an antibody to Bcl-2. GAPDH immunoblot was used as 
constitutive protein control to normal protein loading in each sample. The results 
were repeated with one independent treatment (n=2). 
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I 1 I 2 I 3 I 4 丨 5 丨 6 I 7 I 8 I 9 丨10丨11丨12丨13|14丨15|16 
Tau Hyperphosphorylation y Y 
Reduction 
Caspase-3 Reduction � " ^ ^ " y ^ � 
BCL-2 Increase "y "y 
Tau Hyperphosphorylation ^ � � “ 7 
Reduction 
Caspase-3 Reduction Y Y 
BCL-2 Increase " y 
Table 4.1: Summary of the protective effects of flavonoids against OA—induced 
tau PHF hyperphosphorylation, caspase-3 and Bcl-2 changes in differentiated 
SH-SY5Y cells. The label Y indicated the presence of changes. 
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4.4.4 The effect of different concentrations of hesperidin on OA treatment 
From the preliminarly results, it was found that hesperidin could significantly reverse 
the tau phosphorylation at site ser202 and the activation of active forms of caspase 3 
induced by OA. On the other hand, hesperidin could enchance the induction of Bc-2 
level. Taken these together, it appears that hesperidin may have beneficial protective 
effect against the tau induced cell toxicity. To confirm this，different concentrations of 
hesperidin and hesperitin, an aglycone of hesperidin, were examined, Figures 4.7 
showed that hersperidin at 1-10 uM is effective in reducing the PFF tau phosphoryation, 
whereas hesperitin failed to reverse the PHF phosphorylation. The active form of 
caspase 3 was also reduced by hesperidin. Moreover, hesperidin treatments induced the 
Bcl-2 protein level. In contrast, hesperitin, could not show an obvious reduction of tau 
phosphorylation. 
Figures 4.8 showed the flow cytometry analysis of early apoptotic cells after different 
concentrations of hesperidin in addition to OA treatments. After okadaic acid (50 nM) 
treatment, the percentage of normal cells decreased from 96.59% (control: DMSO) to 
83.86% (50 nM OA) while the apoptotic cells increased from 1.2% (Control: DMSO) 
to 4.56% (50 nM OA). For the late apoptotic and necrotic cells, they showed an 
increase from 1.55% (Control: DMSO) to 11.02% (50 nM OA) (Table 4.2). Hesperdin 
pre-treatment was however unable to protect apoptotic cell death. A slightly decrease 
on the percentage of necrotic cells from 11.02% (50 nM OA) to 8.77% (1 |iM 
Hesperidin + 50 nMOA) was observed. 
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Fig. 4.7: Effects of of different concentrations of hesperidin and hesperetin, 
on okadaic acid (OA) induced PHF phosphorylation, caspase-3 activation 
and Bcl-2 expression. The differentiated SH-SY5Y cells were pretreated with 
different concentrations of hesperidin and hesperetin for 24 hours, followed by 50 
nM okadaic acid for 18 hours. Cell lysates were subjected to Western blots against 
antibodies to PHF-AT8, caspase-3, and Bcl-2. GAPDH immunoblot was used as a 
constituitive positive control. The results were repeated with one independent 
treatment (n=2). 
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Fig. 4.8: Flow cytometry analysis after pre-treatment with different 
concentrations of hesperidin on OA-induced apoptosis. Differentiated SH-SY5Y 
cells were pretreated with different concentrations of hesperidin for 24 hours, 
followed by 50 nM okadaic acid for 18 hours. Cells were stained with Annexin V 
with propidium iodide as described in Section 2.6. After staining, the cell populations 
were analyzed by flow cytometer. Region I: Pl-negative/annexinV-negative, Region 
II: Pl-negative/ annexinV-positive, III: Pl-positive/ annexin V-positive 
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I. Normal II. Apoptotic III. Necrotic 
Con (DMSO) 96.59% “ 1.20% 一 1.55% 
SOnMOA 83.86% “ 4.56% 11.02% 
luM Hesperidin 86.73% 4.11% 8.77% 
+ SOnMOA 
5\iM Hesperidin 85.41% 4.19% 9.96% 
+ SOnMOA 
lOuM Hesperidin 85.35% 4.35% 9.86% 
+ SOnMOA 
Table 4.2: Percentage of cells in different cell stages after okadaic acid 
treatment. The percentages of cells were calculated by the size of areas at different 
phases in the PI intensity-area histogram plot. 
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4.4.5 Proteomic analysis 
To investigate the mechanism of the effect of hesperdin on okadaic acid-induced 
treatment, proteomic analysis was performed to identify the differences between pairs 
of sample in different conditions i.e. 50nM OA treatment and 5\iM hesperidin 
treatment followed with 50nM OA treatment. After gel electrophoresis and staining, 
the two-dimensional gels were scanned to obtain digital photographs which were then 
analyzed by Image master 2D platinum Software (Fig. 4.9 and 4.10). Spots on each gel 
were paired according to their positions. If the volume of one spot was increased or 
decreased more than fifty percent compared to its pair spot，it was distinguished as 
differentially expressed proteins and was then excised for in gel digestion and MALDI-
TOF mass spectrometry. 
There were a total nineteen spots identified (Table 4.3). Spots 1 to 9 were excised from 
the 2 DE gel with 50nM OA-treatment, showing that the volume of the spots increased 
more than fifty percent compared to that of their pair spots. Spots 10-18 were excised 
from the 2 DE gel with 5|iM hesperidin treatment followed by 50nM OA treatment. 
Table 5 showed the protein identity as determined by MALDI-TOF tandem mass 
spectrometry. The protein name, accession, observed and theoretical MW, observed 
and theoretical pi are shown. 
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Fig. 4.9: 2-DE pattern of SOnM okadaic acid treatment on differentiated SH-
SY5Y cells. Sample were resolved by 2-DE on pH 3-10 IPG strips followed by 
separation on a 12% SDS-PAGE gel in the second dimension. Proteins were 
visualized by SYBRO Ruby staining. 
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Fig. 4.10: 2-DE pattern of S^M hesperidin treatment followed with 50nM 
okadaic acid treatment on differentiated SH-SY5Y cells. Sample were resolved 
by 2-DE on pH 3-10 IPG strips followed by separation on a 12% SDS-PAGE gel 
in the second dimension. Proteins were visualized by SYBRO Ruby staining. 
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Observed Observed 
/Theoretical /Theoretical Volume of Volume of 
Protein Accession MW (kPa) PI (kPa) Spots Paired Spots 
1 Myosin Heavy chain 3 P11055 100.2/224.00 7.03/5.64 0.773 0.211 
2 Fascin Q16658 61.10/54.50 7.21/6.84 2.106 0.477 
26S protease Regulatory 
3 Subunit? P35998 37.52/48.60 7.05/5.71 0.753 0.462 
4 Adenosylhomocysteinase P23526 56.35/47.68 6.15/6.03 1.561 0.804 
Ubiquitin carboxyl-terminal 
5 hydroxylase isozyme 1 P09936 25.11/24.81 5.63/5.33 1.365 0.561 
6 Antioxidant protein 2 P30041 25.98/24.89 6.58/6.02 1.365 0.915 
7 GTP-binding nuclear protein P28746 24.15/24.41 7.19/7.01 0.248 0.279 
Nucleoside diphosphate 
8 kinase A P15531 18.35/17.14 5.78/5.83 0.420 0.373 
9 Cofilin P23528 16.35/18.49 6.15/8.22 1.106 0.682 
10 SCAM-1 Protein gi|14603385 43.52/36.72 8.89/8.86 0.242 0.862 
Rho gdp-dissociation inhibitor 
11 1 P52565 39.11/23.19 8.12/5.02 0.381 1.293 
Heterogeneous nuclear 
12 ribonucleoproteins A2/B1 P22626 37.22/37.41 9.11/8.97 0.537 2.708 
Heat shock cognate 71KD 
13 protein P19120 48.45/71.20 4.75/5.49 0.666 2.708 
Guanine nucleotide binding 
14 protein G(Q) alpha subunit P50148 21.22/41.40 7.02/5.58 0.433 0.734 
15 Thioredoxin peroxidase 2 P32119 23.50/22.10 9.02/8.27 0.350 1.503 
51 KD FK506-Binding protein 
16 (FKBP51) Q13451 12.50/51.00 5.21/5.71 0.270 0.286 
Peptidyl-prolyl cis/trans 
17 isomerase A P05092 15.36/17.87 8.12/7.82 0.763 0.543 
Peptidyl-prolyl cis/trans 
18 isomerase A P05092 15.36/17.87 8.93/7.82 0.477 1.064 
19 Cofilin P45592 21.35/18.52 9.11/8.22 0.154 0.279 
Table 4.3: Differential expressed proteins in 50nM okadaic acid treatment and 
hesperidin treatment followed with 50nM okadaic acid treatment. Spots on each 
gel were paired according to their positions. The volume of the spots increased more 
than fifty percent compared to that of their pair spots. 
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4.5 Discussion 
After establishing the okadaic acid-induced apoptosis cell model, the model was 
characterised and showed that it can mimic some molecular or morphological 
changes in Alzheimer's disease affected neurons, including increase of 
phosphorylated tau protein and Bcl-2 levels，increase of pro and active caspase 3 
levels, neurite retraction, nucleus condensation and also increase of apoptotic 
cells. In this study, thirty two flavonoids were tested to search for any potential 
drugs that can protect against tau hyperphosphorylation and prevent or delay 
neuronal cell death. Flavonoids are a large group of naturally occurring, low 
molecular weight, polyphenolic compounds widely distributed in plant and fruit. 
They have important roles in plant growth, reproduction, and pathogen resistance 
(Harbome and Williams, 1992). In general, flavonoids appear to be non-toxic but 
some flavonoids have shown to have apoptotic effects on cancer cells when given 
at high concentration, e.g. 50 |a,M luteolin caused a apoptotic effect in human 
LNCaP prostate cancer cell line (Brusselmans et al., 2005). 
In this study, flavonoids that were examined here have minimal cell toxicity at 
concentraton of 5 [iM. Over 90% cell viability was found after 24 hours treatment 
of these flavanoids except casticin which has a slight increase in cell death. When 
the differentiated SH-SY5Y cells were treated with 50nM OA, the cells appeared 
neurite retraction and became roundish. When the cells were treated with 5jiM 
flavonoids in addition to 50nM OA treatment, they still showed severe neurite 
retraction similar to those treated with 50nM OA only. Moreover, the MTT assay 
also indicated that most flavonoids could not reverse the amount of cell death 
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induced by the okadaic acid. The results suggested that the tested flavonoids are 
not able to offset the cytotoxicity and neurite retraction induced by OA. 
After okadaic treatment, the expression levels of phosphorylated tau at site 
Ser202 and pro and active forms of caspase 3 were increased, and the anti-
apoptotic protein Bcl-2 level was also induced due to the protective mechanism 
stimulated by the toxicity and stress of OA. When the cells were treated with 5|xM 
flavonoids in addition to 50nM OA treatment, six flavonoids showed the ability to 
reduce the tau hyperphosphorylation at site ser202 and nine flavonoids were 
found to reduce the levels of both pro and active forms of caspase 3. Moreover, 
six flavonoids showed induction of Bcl-2 levels. Among these flavonoids，only 
hesperidin could reverse the tau phosphorylation at site ser202 and the 
upregulation of pro and active forms of caspase 3, also heperidin could induce 
Bcl-2 level. However, the protective effects observed in the molecular changes 
were not enough to terminate the apoptotic mechanisms induced by OA. Since 
studies reported that okadaic acid could increase the phosphorylation of p53 
without changing p53 levels, which in turn activated the apoptotic pathways (Yan 
et al,, 1997). This data indicate that the reduction of tau hyperphosphorylation is 
not a sufficient condtion to protect the apoptosis induced by OA. Nevertheless, 
the findings that hesperidin significantly reduce the PHF formation is interesting, 
in the light of the fact that of PHF formation is tightly associated with tangly 
formation which cause Alzheimer's disease progression. 
Hesperidin, a bioflavonoid, is abundant and inexpensive by-product of Citrus 
cultivation and is the major flavonoid in the sweet orange and lemon. No signs of 
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toxicity have been observed with the normal intake of hesperidin (Pizzomo and 
Murray, 1999). Hesperidin has been reported to possess significant anti-
inflammatory and analgesic effects. Moreover, when in combination with diosmin, 
hesperidin shows a marked protective effect against inflammation disorder, 
possibly through mechanism involving antioxidant free radical scavenger activity 
(Jean and Bodinier, 1994). Thus, it may relieve oxidative stress and 
neuroinflammation, which may protect brain aging and neurodegenerative 
diseases. Here hesperidin is shown to have selective reduction of tau 
phosphorylation and caspase 3 levels, and increase of Bel 2 levels mediated by 
OA induced apoptosis. 
Hesperidin, but not an aglycone hesperitin, was found to have a concentration-
dependent protection of PHF-tau phoshorylation. This indicated that the glycoside 
of hesperidin is necessary for its action. Previous results showed that no flavonoid 
could protect cell death measured by MTT assay. However, instead of cell death, 
early apoptotic cells detected by annexin V can also be monitored to validate the 
neuroprotection effect of different concentrations of hesperidin. However, Figures 
4.8 showed hesperdin could not prevent apoptotic cell death but just slightly 
decrease the percentage of necrotic cells from 11.02% (50nM OA) to 8.77% 
(\ \ iU Hesperidin + 50nMOA). 
In conclusion, hesperidin has shown the protective ability on reduction of 
phosphorylated tau and caspase 3 levelsl as well as the induction of the anti-
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apoptotic protein Bcl-2 level. However, these changes were not enough to 
terminate the apoptotic signal induced by OA 
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Chapter 5: General discussion 
Alzheimer's disease (AD) is the most common form of neurodegenerative disease 
characterized by loss of memory and cognitive abilities which interfere with 
normal activities of daily living. The disease is hallmarked by a decline in 
cognitive functions such as remembering, reasoning, and planning. The 
deterioration of cognitive and motor functions is mainly related to the loss of 
neuron in the basal forebrain of Alzheimer's disease patient. With the intensive 
study of AD for over three decades, many causes of the disease pathogenesis are 
proposed. Some of these causes are closely related to each other and observed in 
AD patients. This suggests that many causes or factors work together to achieve 
the ultimate target: neuronal cell death. These causes or factors include protein 
misfolding and aggregation i.e. (3-amyloid plaque and neurofibrillary tangles, 
gene mutations i.e. Mutations of presenilin 1 gene, amyloid precursor protein 
gene and apolipoprotein E gene, loss of cholinergic neurotransmission and also 
generation of free radical and neuroinflanimation. 
Until now, there is no treatment for Alzheimer's disease and the available 
medications, acetylcholine esterase inhibitors, only offer symptomatic benefit for 
some patients but can not slow down the progression. Acetylcholine esterase 
inhibitors reduce the rate at which acetylcholine (ACh) is broken down and hence 
increase the concentration of ACh in the brain. These drugs can temporarily 
stabilize cognitive impairment and maintain body muscle functions; however, 
they cannot reverse or stop the disease progression and may not show the 
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beneficial effects in some patients. Thus, designing other mechanism-based drugs 
is the direction to alter disease pathology and progression. 
In tauopathy hypothesis, the formation of paired helical filaments composed of 
hyperphosphorylated tau protein is a key pathologic molecular change contributed 
to the neurodegeneration. Thus, preventing tau phosphorylation is one of the 
strategies to reverse or stop the disease progression. In this study, we aimed at 
establishing an okadaic acid-induced apoptosis cell line model that can be used to 
search for any potential flavonoids against tau hyperphosphorylation and cell 
death. The first part of this study was to characterize the cell model and examine 
whether it can mimic some cellular and biochemical changes in Alzheimer's 
disease affected neurons. The results showed that okadaic acid treatment caused 
an increase in PHF-tau protein level and activation of caspase-3 mediated 
apoptotic cell death. Moreover, after treatment, the neuroblastama cells showed 
neurite retraction, and both the cell death and apoptotic cells increased, measured 
by several methods including the MTT assay, cell cycle analysis and annexin V 
staining. Studies on AD brains also demonstrated tau hyperphosphorylation and 
showed characteristic of programmed cell death. The findings indicate that OA 
treatment of neuroblastoma cells mimics the characteristics of cellular and 
biochemical changes associated with tau hyperphosphorylation-induced neuronal 
cell death of Alzheimer's disease. 
After characterization, the model was then used to screen for any potential 
flavonoids that can prevent tau hyperphosphorylation and neuronal cell death. 
The toxicity test of flavonoid showed that most flavonoids in a concentration of 5 
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P-M had less toxicity, except casticin. In the western blot analysis, six flavonoids 
showed reduction of tau hyperphosphorylation at site ser202 and nine flavonoids 
were found to suppress the levels of both pro and active forms of caspase 3. 
Moreover, six flavonoids induced Bcl-2 levels. However, the results indicated 
that 32 flavonoids at a concentration of 5 |iM could not protect the cells from 
neurite retraction and could not show protection of the cell death induced by 
okadaic acid. This suggested that the protective effects observed in the molecular 
changes were not enough to terminate the apoptotic mechanisms induced by OA. 
Since studies reported that okadaic acid could induce other apoptotic pathways 
instead of caspase 3 mediated apoptosis induced by tau hyperphosphorylation. 
Among the thirty two flavonoids, only hesperidin could reverse the tau 
phosphorylation at site ser202 and downregulate the levels of pro and active 
forms of caspase 3, also induce BCL-2 level. Thus, different concentrations of 
hesperidin on OA treatment were used to confirm the protection effect on 
molecular changes observed in previous results. The findings indicated that that 
different concentration of hesperidin could reduce the tau phosphoryation, active 
form of caspase 3 levels and induced the BCL 2 protein level. And these effects 
maintained even at low concentration (l|iM) of hesperidin. However, hesperitin, 
an aglycone of hesperidin, could not show such effects, indicating that the 
glycoside of heperidin was necessary for its protective action. Again, the annexin 
V-PI staining results showed that hesperdin could not prevent apoptotic cell death 
but just slightly decrease the percentage of necrotic cells from 11.02% (50nM OA) 
to 8.77% (IjaM Hesperidin + 50nMOA). This may be due to the activation of 
other apoptotic pathways induced by okadaic acid, so the reverse of caspase 3 
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mediated pathway induced by tau hyperphosphorylation was not enough to 
terminate the process. 
The study of the proteome, which is the PROTEin complement expressed by a 
genOME, has developed remarkably over the past few years. It provides 
information about the state of gene products, such as the expression levels and 
isoform. Two-dimensional gel electrophoresis (2-DE), which consists of 
isoelectric electrophoresis focusing (lEF) and sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS PAGE) is an effective method of 
separating a large number of proteins，providing a new platform for studies of 
complex biological functions. In order to investigate the mechanism of the 
protective effect of hesperidin, proteomic analysis was carried out. There were 
total nineteen differentially expressed protein spots identified. Spots 1 to 9 were 
excised from the 2 DE gel with 50nM OA-treatment while Spots 10-18 were 
excised from the 2 DE gel with 5|iM hesperidin treatment followed by 50nM OA 
treatment. All the spots were screened out by the criteria that the volume of one 
spot was increased more than fifty percent compared to its pair spot. Among 
these identified spots, peptidyl-prolyl isomerase A (Pin 1) was found to be 
upregulated in heperidin treatment in addition to OA treatment. Since Pin 1 can 
catalyze the cis-trans isomerization of peptidyl-prolyl bonds (Liou et al., 2003). 
After isomerization, the spatial arrangement of phosphate on ser/Thr is different 
(Figure 5.1). 
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Fig. 5.1： Cis-trans isomerization of peptidyl-prolyl bonds catalysed by Pin 1 
Studies have shown that phosphorylatied tau also contains such motif and is one 
of the substrate for Pin 1. Pin 1 can catalyze the isomerization of the cis-form of 
phosphorylated tau to the trans-form of phosphorylated tau, which is more easily 
to be dephosphorylated by protein phosphatase 2A, so the function of tau can be 
restored. Moreover, after knocking out the Pin 1 gene of the mice, tau 
hyperphosphorylation increased and neurodegeneration was observed. All of this 
suggested that Pin 1 may involve in protecting against AD. Thus, upregulation of 
Pin 1 by hesperidin may be involved in the reverse of tau hyperphosporylation 
and caspase-3 mediated apoptosis pathway. However, proteomic analysis is just a 
preliminary study to find out the differential expressed protein. The results need 
to be confirmed by the western blot technique applied on the 2-D gels using 
antibody against the proteins. 
In summary, the okadaic acid induced apoptosis model was characterized, which 
mimicked the biological and cellular changes observed in AD. Among the tested 
flavonoids, hesperidin has shown the protective ability on reduction of 
phosphorylated tau and caspase 3 levels, also induction of BCL-2 level but these 
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molecular changes were not enough to terminate the apoptotic signal induced by 
OA. Preliminary proteomic analysis was carried out to find the differential 
expressed proteins which involved in the protective mechanism of hesperidin. Pin 
1 was found to be upregulated and showed the ability to reduce tau 
hyperphosphorylation, which validate to the findings of the effect of hesperidin. 
In the future, confirmation of the differential expressed protein by 2D western 
blot analysis is needed and the protective mechanisms can be studied by 
suppression or overexpression of those differential expressed proteins to find the 
relationship with tau phosphorylation and the intermediate involved in the 
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